User Image Cart Icon 0 Search Image
  • Home > Blog > Dipeptidyl peptidase 4 inhibitors

Dipeptidyl peptidase 4 inhibitors

  1. Comparative review of dipeptidyl peptidaseโ€4 inhibitors and sulphonylureas
  2. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences
  3. Dipeptidyl peptidaseโ€4 (DPPโ€4) inhibitors for type 2 diabetes mellitus
  4. Safety of dipeptidyl peptidase 4 inhibitors: a perspective review
  5. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors
  6. Dipeptidyl peptidaseโ€4 inhibitors in the treatment of type 2 diabetes: a comparative review
  7. Whey proteins as source of dipeptidyl dipeptidase IV (dipeptidyl peptidase-4) inhibitors
  8. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4)
  9. Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions
  10. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors
  11. The nonglycemic actions of dipeptidyl peptidase-4 inhibitors
  12. Dipeptidyl peptidase-4 (DPP-4) inhibitors in the management of diabetes
  13. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials
  14. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus
  15. A review of dipeptidyl peptidaseโ€4 inhibitors. Hot topics from randomized controlled trials
  16. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials
  17. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes
  18. Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions
  19. Tolerability of dipeptidyl peptidase-4 inhibitors: a review
  20. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis
  21. Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes
  22. Dipeptidyl peptidase-4 inhibitors: 3 years of experience
  23. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis
  24. Dipeptidyl peptidaseโ€4 inhibitors for the treatment of type 2 diabetes mellitus
  25. Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials
  26. Predictors of response to dipeptidyl peptidaseโ€4 inhibitors: evidence from randomized clinical trials
  27. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes
  28. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety
  29. Dipeptidyl peptidaseโ€4 inhibitors and cardiovascular risk: a metaโ€analysis of randomized clinical trials
  30. Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice
  31. Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors
  32. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus
  33. Dipeptidyl peptidaseโ€4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin
  34. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes
  35. Dipeptidyl peptidaseโ€4 inhibitors and cardiovascular outcomes: metaโ€analysis of randomized clinical trials with 55,141 participants
  36. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: a meta-analysis
  37. Dipeptidylโ€peptidaseโ€4 inhibitors and pancreatic cancer: a cohort study
  38. Exposure to dipeptidylโ€peptidaseโ€4 inhibitors and COVIDโ€19 among people with type 2 diabetes: a caseโ€control study
  39. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis
  40. Role of dipeptidyl peptidase 4 inhibitors in antidiabetic treatment
  41. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials
  42. Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors
  43. Longer term safety of dipeptidyl peptidaseโ€4 inhibitors in patients with type 2 diabetes mellitus: systematic review and metaโ€analysis
  44. Dipeptidyl peptidase-4 inhibitors cause bullous pemphigoid in diabetic patients: report of two cases
  45. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
  46. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus
  47. The effects of dipeptidyl peptidaseโ€4 inhibitors on kidney outcomes
  48. Dipeptidyl peptidase-4 inhibitors and osteoporosis
  49. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis
  50. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase
  51. Dipeptidyl peptidase 4 inhibitors: Applications in innate immunity?
  52. Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks?
  53. Dipeptidyl peptidaseโ€4 inhibitors and sulfonylureas for type 2 diabetes: friend or foe?
  54. Dipeptidyl peptidaseโ€4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLPโ€1
  55. Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases
  56. Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: a meta-analysis with trial sequential analysis
  57. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study
  58. Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus
  59. Effect of dipeptidyl peptidase-4 inhibitors on heart failure: a meta-analysis of randomized clinical trials
  60. Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes: estimating the risk of the new agents and characterizing the patients
  61. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapyโ€“focus on alogliptin
  62. Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study
  63. Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture
  64. No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19
  65. Dipeptidyl peptidaseโ€4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment
  66. Dipeptidyl peptidaseโ€4 inhibitors and HbA1c target of< 7% in type 2 diabetes: metaโ€analysis of randomized controlled trials
  67. A case report of bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors
  68. Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus
  69. Effects on clinical outcomes of adding dipeptidyl peptidase-4 inhibitors versus sulfonylureas to metformin therapy in patients with type 2 diabetes mellitus
  70. Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinsonโ€™s disease
  71. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies
  72. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors
  73. Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes
  74. Dipeptidyl peptidaseโ€4 inhibitors attenuate endothelial function as evaluated by flowโ€mediated vasodilatation in type 2 diabetic patients
  75. The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
  76. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortalityย โ€ฆ
  77. Dipeptidyl peptidaseโ€4 inhibitors and pancreatitis risk: a metaโ€analysis of randomized clinical trials
  78. Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors
  79. Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment
  80. Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in Type 2 diabetes management
  81. Effect of dipeptidyl peptidase-4 inhibitors on bone metabolism and the possible underlying mechanisms
  82. Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis
  83. Dipeptidyl peptidase-4 inhibitors have protective effect on cognitive impairment in aged diabetic patients with mild cognitive impairment
  84. Can dipeptidyl peptidase-4 inhibitors treat cognitive disorders?
  85. Association between hospitalization for heart failure and dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: an observational study
  86. Sarcopenia in elderly diabetic patients: role of dipeptidyl peptidase 4 inhibitors
  87. Bullous pemphigoid associated with dipeptidyl peptidaseโ€4 inhibitors: a report of five cases
  88. Is there an association between dipeptidyl peptidase-4 inhibitors and autoimmune disease? A population-based study
  89. Risk of dipeptidyl peptidaseโ€4 (DPPโ€4) inhibitors on siteโ€specific cancer: A systematic review and metaโ€analysis
  90. Efficacy and safety of dipeptidyl peptidaseโ€4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: aย โ€ฆ
  91. Bullous pemphigoid induced by dipeptidyl peptidaseโ€4 inhibitors. Eight cases with clinical and immunological characterization
  92. Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control
  93. Impact of comorbidities and glycemia at admission and dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes with COVID-19: a case series from anย โ€ฆ
  94. Unique clinical and serological features of bullous pemphigoid associated with dipeptidyl peptidaseโ€4 inhibitors
  95. Use of dipeptidyl peptidaseโ€4 inhibitors and prognosis of COVIDโ€19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADOย โ€ฆ
  96. Dipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials
  97. Dipeptidyl peptidase-4 (DPP-4) inhibitors: promising new agents for autoimmune diabetes
  98. Dipeptidyl peptidaseโ€4 inhibitors and preservation of pancreatic isletโ€cell function: a critical appraisal of the evidence
  99. The place of dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapeutics: a โ€œme tooโ€ or โ€œthe special oneโ€ antidiabetic class?
  100. Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis
  101. Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes: a systematic review and meta-analysis
  102. The role of dipeptidyl peptidaseโ€“4 inhibitors in diabetic kidney disease
  103. Recent advances in non-peptidomimetic dipeptidyl peptidase 4 inhibitors: medicinal chemistry and preclinical aspects
  104. โ€ฆย of the binding properties, dipeptidyl peptidaseโ€4 (DPPโ€4) inhibitory activity and glucoseโ€lowering efficacy of the DPPโ€4 inhibitors alogliptin, linagliptin, saxagliptinย โ€ฆ
  105. Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials
  106. Comparative analysis of binding kinetics and thermodynamics of dipeptidyl peptidase-4 inhibitors and their relationship to structure
  107. Design, synthesis and anti-diabetic activity of triazolotriazine derivatives as dipeptidyl peptidase-4 (DPP-4) inhibitors
  108. Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and metaย โ€ฆ
  109. Three cases of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors-one due to linagliptin
  110. Renal outcomes with dipeptidyl peptidase-4 inhibitors
  111. Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?
  112. Dipeptidyl peptidase-4 inhibitors can inhibit angiotensin converting enzyme
  113. โ€ฆย therapies: highlighting common features and differences in the modes of action of glucagonโ€like peptideโ€1 receptor agonists and dipeptidyl peptidaseโ€4 inhibitors
  114. Dipeptidyl peptidaseโ€4 inhibitors can minimize the hypoglycaemic burden and enhance safety in elderly people with diabetes
  115. Bullous pemphigoid induced by dipeptidyl peptidase-4 (DPP-4) inhibitors: a pharmacovigilance-pharmacodynamic/pharmacokinetic assessment through an analysisย โ€ฆ
  116. Dipeptidyl peptidase 4 inhibitors and the risk of bullous pemphigoid among patients with type 2 diabetes
  117. Dipeptidyl peptidase-4 inhibitors: Anti-diabetic drugs with potential effects on cancer
  118. A comprehensive review and perspective on natural sources as dipeptidyl peptidase-4 inhibitors for management of diabetes
  119. Dipeptidyl peptidase 4 inhibitors and the risk of cardiovascular disease in patients with type 2 diabetes: a tale of three studies
  120. Effects of dipeptidyl peptidase-4 inhibitors on renal outcomes in patients with type 2 diabetes: a systematic review and meta-analysis
  121. Pancreatitis and pancreatic cancer in patientes treated with Dipeptidyl Peptidase-4 inhibitors: An extensive and updated meta-analysis of randomized controlled trials
  122. Dipeptidyl peptidase 4 inhibitors reduce hepatocellular carcinoma by activating lymphocyte chemotaxis in mice
  123. Glycaemic efficacy of glucagonโ€like peptideโ€1 receptor agonists and dipeptidyl peptidaseโ€4 inhibitors as addโ€on therapy to metformin in subjects with type 2 diabetesย โ€ฆ
  124. Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidaseโ€4 inhibitors and sulphonylureas: a primary careย โ€ฆ
  125. Combination therapy of dipeptidyl peptidaseโ€4 inhibitors and metformin in type 2 diabetes: rationale and evidence
  126. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wideย โ€ฆ
  127. Dipeptidyl peptidase-4 inhibitors and protection against stroke: A systematic review and meta-analysis
  128. Longโ€term use of dipeptidyl peptidaseโ€4 inhibitors and risk of fracture: a retrospective populationโ€based cohort study
  129. The dipeptidylโ€peptidaseโ€4 (DPPโ€4) inhibitors: a new class of oral therapy for patients with type 2 diabetes mellitus
  130. Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner
  131. Roles and mechanisms of dipeptidyl peptidase 4 inhibitors in vascular aging
  132. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes
  133. Dipeptidyl-peptidase-4 inhibitors and heart failure: class effect, substance-specific effect, or chance effect?
  134. Effect of dipeptidyl peptidase 4 inhibitors on acute and subacute models of inflammation in male Wistar rats: an experimental study
  135. The pleiotropic cardiovascular effects of dipeptidyl peptidaseโ€4 inhibitors
  136. The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials
  137. Dipeptidyl peptidaseโ€4 inhibitorsโ€associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients
  138. Cost-effectiveness analysis of metformin+ dipeptidyl peptidase-4 inhibitors compared to metformin+ sulfonylureas for treatment of type 2 diabetes
  139. Dipeptidyl peptidase-4 inhibitors and risk of arthralgia: a systematic review and meta-analysis
  140. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes
  141. Dipeptidyl peptidase-4 inhibitors in chronic kidney disease: a systematic review of randomized clinical trials
  142. The effect of dipeptidyl peptidase-4 inhibitors on macrovascular and microvascular complications of diabetes mellitus: a systematic review
  143. Diabetes: Rationale for Dipeptidyl Peptidase 4 Inhibitors: A New Class of Oral Agents for the Treatment of Type 2 Diabetes Mellitus
  144. Serum and adipose dipeptidyl peptidase 4 in cardiovascular surgery patients: influence of dipeptidyl peptidase 4 inhibitors
  145. Dipeptidyl peptidase-4 inhibitors improve arterial stiffness, blood pressure, lipid profile and inflammation parameters in patients with type 2 diabetes mellitus
  146. Gastrointestinal adverse events of dipeptidyl peptidase 4 inhibitors in type 2 diabetes: a systematic review and network meta-analysis
  147. Effectiveness and safety of sodiumโ€glucose coโ€transporterโ€2 inhibitors compared with dipeptidyl peptidaseโ€4 inhibitors in older adults with type 2 diabetes: Aย โ€ฆ
  148. Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes
  149. Dipeptidyl peptidaseโ€4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: a nationwide populationโ€based cohort study
  150. Effects of dipeptidyl peptidase 4 inhibitors and sodium-glucose linked cotransporter-2 inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: aย โ€ฆ
  151. Dipeptidyl peptidaseโ€4 inhibitors, glucagonโ€like peptide 1 receptor agonists and sodiumโ€glucose coโ€transporterโ€2 inhibitors for people with cardiovascular disease: aย โ€ฆ
  152. The safety of dipeptidyl peptidaseโ€4 (DPPโ€4) inhibitors or sodiumโ€glucose cotransporter 2 (SGLTโ€2) inhibitors added to metformin background therapy in patients withย โ€ฆ
  153. Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germanyโ€”a retrospective analysis of real-world data
  154. Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials
  155. Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials
  156. Dipeptidyl peptidase-4 inhibitors and diabetic kidney disease: a narrative review
  157. Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of cardiovascular outcome trials
  158. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials
  159. Effect of dipeptidyl peptidase-4 inhibitors on heart failure: a network meta-analysis
  160. The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study
  161. Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials
  162. Dipeptidyl peptidaseโ€4 inhibitors and bullous pemphigoid: A systematic review and adjusted metaโ€analysis
  163. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with moderate to severe renal impairment: a systematic review andย โ€ฆ
  164. Heart failure and dipeptidyl peptidaseโ€4 inhibitors
  165. Safety of dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes
  166. Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial
  167. A review on cardiovascular outcome studies of dipeptidyl peptidase-4 inhibitors
  168. Do dipeptidyl peptidase-4 inhibitors increase the risk of heart failure?
  169. Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents
  170. Dipeptidyl peptidaseโ€4 inhibitors moderate the risk of genitourinary tract infections associated with sodiumโ€glucose coโ€transporterโ€2 inhibitors
  171. Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study
  172. Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: An extensive meta-analysis of randomizedย โ€ฆ
  173. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in patients with type 2 diabetes mellitus: a population-based cohort study
  174. QSAR study of dipeptidyl peptidase-4 inhibitors based on the Monte Carlo method
  175. Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal cancer and lung cancer: A Surveillance Epidemiology andย โ€ฆ
  176. Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stemย โ€ฆ
  177. Bullous pemphigoid and dipeptidyl peptidase 4 inhibitors: a disproportionality analysis based on the Japanese adverse drug event report database
  178. Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy
  179. Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes
  180. Oral diabetes medications other than dipeptidyl peptidase 4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study
  181. Mechanisms of neurodegeration in type 2 diabetes and the neuroprotective potential of dipeptidyl peptidase 4 inhibitors
  182. Efficacy and safety of sodiumโ€glucose cotransporterโ€2 inhibitors versus dipeptidyl peptidaseโ€4 inhibitors as monotherapy or addโ€on to metformin in patients with typeย โ€ฆ
  183. Comparative safety of dipeptidyl peptidaseโ€4 inhibitors and sulfonylureas among frail older adults
  184. Effects of dipeptidyl peptidaseโ€4 inhibitors and sulphonylureas on cognitive and physical function in nursing home residents
  185. Dipeptidyl peptidase-4 inhibitors and COVID-19-related deaths among patients with type 2 diabetes mellitus: a meta-analysis of observational studies
  186. Lower cardiorenal risk with sodiumโ€glucose cotransporterโ€2 inhibitors versus dipeptidyl peptidaseโ€4 inhibitors in patients with type 2 diabetes without cardiovascularย โ€ฆ
  187. Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world useย โ€ฆ
  188. Comparative safety of dipeptidyl peptidase-4 inhibitors versus sulfonylureas and other glucose-lowering therapies for three acute outcomes
  189. Dipeptidyl peptidase-4 inhibitors attenuates osteoporosis in patients with diabetes: a nationwide, retrospective, matched-cohort study in Taiwan
  190. Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting
  191. Bullous pemphigoid with dipeptidyl peptidaseโ€4 inhibitors: Clinical features and pathophysiology
  192. Emerging roles of dipeptidyl peptidase-4 inhibitors in delaying the progression of type 1 diabetes mellitus
  193. Impact of dipeptidyl peptidase-4 inhibitors on serum adiponectin: a meta-analysis
  194. Comparative safety of sodiumโ€“glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors and sulfonylureas on the risk of diabetic ketoacidosis
  195. The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes
  196. The emerging role of dipeptidyl peptidase-4 inhibitors in cardiovascular protection: current position and perspectives
  197. Navigating the chemical space of dipeptidyl peptidase-4 inhibitors
  198. Mechanism by which dipeptidyl peptidase-4 inhibitors increase the risk of heart failure and possible differences in heart failure risk
  199. Use of dipeptidyl-peptidase-4 inhibitors and the risk of pneumonia: a population-based cohort study
  200. Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: a nationwide, populationโ€based, cohort study in Taiwan
  201. Predictive factors for efficacy of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus
  202. Wound healing effects of dipeptidyl peptidase-4 inhibitors: an emerging concept in management of diabetic foot ulcerโ€”a review
  203. โ€ฆย -onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors
  204. The effects of dipeptidyl peptidase-4 inhibitors on cardiovascular disease risks in type 2 diabetes mellitus
  205. Dipeptidyl peptidase-4 inhibitors, peripheral arterial disease, and lower extremity amputation risk in diabetic patients
  206. Direct headโ€toโ€head comparison of glycaemic durability of dipeptidyl peptidaseโ€4 inhibitors and sulphonylureas in patients with type 2 diabetes mellitus: A metaย โ€ฆ
  207. Dipeptidyl peptidase 4 (DPP-4) inhibitors and the risk of lung cancer: Current evidence and future directions
  208. Effects of dipeptidyl peptidase-4 inhibitors on cardiac and endothelial function in type 2 diabetes mellitus: A pilot study
  209. โ€ฆย ), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors
  210. Addition of dipeptidyl peptidaseโ€4 inhibitors to insulin treatment in type 2 diabetes patients: a metaโ€analysis
  211. Dipeptidyl peptidase-4 inhibitors: a new approach in diabetes treatment
  212. Dipeptidyl peptidase-4 inhibitors and their potential role in the management of atherosclerosisโ€”A review
  213. The effects of dipeptidyl peptidase-4 inhibitors on bone fracture among patients with type 2 diabetes mellitus: a network meta-analysis of randomizedย โ€ฆ
  214. Nationwide trends in pancreatitis and pancreatic cancer risk among patients with newly diagnosed type 2 diabetes receiving dipeptidyl peptidase 4 inhibitors
  215. Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetesย โ€ฆ
  216. Pharmacology of dipeptidyl peptidase-4 inhibitors and its use in the management of metabolic syndrome: a comprehensive review on drug repositioning
  217. Combination of vitamin D and dipeptidyl peptidase-4 inhibitors (VIDPP-4i) as an immunomodulation therapy for autoimmune diabetes
  218. Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: systematic review andย โ€ฆ
  219. Association of hemoglobin A1c levels with use of sulfonylureas, dipeptidyl peptidase 4 inhibitors, and thiazolidinediones in patients with type 2 diabetes treated withย โ€ฆ
  220. โ€ฆย antiโ€inflammatory properties of glucagonโ€like peptideโ€1, glucoseโ€dependent insulinotropic polypepide, and dipeptidyl peptidaseโ€4 inhibitors in experimental animals
  221. Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized controlled trials
  222. Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system
  223. Dipeptidyl peptidaseโ€4 inhibitors and angioedema: a class effect?
  224. Dipeptidyl peptidase-4 inhibitors reduced long-term cardiovascular risk in diabetic patients after percutaneous coronary intervention via insulin-like growthย โ€ฆ
  225. Dipeptidyl peptidase-4 inhibitors and inflammatory bowel disease risk: a meta-analysis
  226. Dipeptidyl peptidase 4 inhibitors decrease the risk of hepatocellular carcinoma in patients with chronic hepatitis C infection and type 2 diabetes mellitus: aย โ€ฆ
  227. Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors: a population-based nested case-control study
  228. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors
  229. The safety of dipeptidyl peptidase 4 inhibitors and the risk for heart failure
  230. Effect of dipeptidyl peptidase-4 inhibitors on postprandial glucagon level in patients with type 2 diabetes mellitus: A systemic review and meta-analysis
  231. Dipeptidyl peptidase-4 inhibitors and heart failure: analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System
  232. Associations of dipeptidyl peptidaseโ€4 inhibitors with mortality in hospitalized heart failure patients with diabetes mellitus
  233. Detection and characterization of IgG, IgE, and IgA autoantibodies in patients with bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors
  234. Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: A real-world Koreanย โ€ฆ
  235. Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis
  236. Protective effects of dipeptidyl peptidase-4 inhibitors on progression of diabetic retinopathy in patients with type 2 diabetes
  237. โ€ฆย between the dipeptidyl peptidase-4 and stromal cell-derived factor-1 in stem cell homing and myocardial repair: potential impact of dipeptidyl peptidase-4 inhibitors
  238. Dipeptidyl peptidase-4 inhibitors in cardioprotection: a promising therapeutic approach
  239. Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease
  240. Cardioprotective effects of dipeptidyl peptidase-4 inhibitors versus sulfonylureas in addition to metformin: a nationwide cohort study of patients with type 2 diabetes
  241. SARS-CoV-2 and diabetes: A potential therapeutic effect of dipeptidyl peptidase 4 inhibitors in diabetic patients diagnosed with COVID-19
  242. โ€ฆย , molecular simulation, and biological activities of novel quinazolinone-pyrimidine hybrid derivatives as dipeptidyl peptidase-4 inhibitors and anticancer agents
  243. Effectiveness and safety of dipeptidyl peptidase 4 inhibitors in the management of type 2 diabetes in older adults: a systematic review and development ofย โ€ฆ
  244. The risk of fragility fractures in new users of dipeptidyl peptidase-4 inhibitors compared to sulfonylureas and other anti-diabetic drugs: a cohort study
  245. Dipeptidyl peptidase-4 inhibitors and the risks of autoimmune diseases in type 2 diabetes mellitus patients in Taiwan: a nationwide population-based cohortย โ€ฆ
  246. Bullous pemphigoid associated with dipeptidyl peptidaseโ€4 inhibitors. A case series and analysis of cases reported in the Spanish pharmacovigilance database
  247. Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study inย โ€ฆ
  248. Cardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure
  249. Neuroprotection by dipeptidyl-peptidase-4 inhibitors and glucagon-like peptide-1 analogs via the modulation of AKT-signaling pathway in Alzheimerโ€™s disease
  250. โ€ฆย -glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase-4 (DPP-4) inhibitors: a systematic review
  251. Association between the use of dipeptidyl peptidase 4 inhibitors and the risk of dementia among patients with type 2 diabetes in Taiwan
  252. Emerging roles of dipeptidyl peptidase 4 inhibitors: anti-inflammatory and immunomodulatory effect and its application in diabetes mellitus
  253. Effects of dipeptidyl peptidaseโ€4 inhibitors on transforming growth factorโ€ฮฒ1 signal transduction pathways in the ovarian fibrosis of polycystic ovary syndrome rats
  254. Persistence to treatment with novel antidiabetic drugs (dipeptidyl peptidase-4 inhibitors, sodium-glucose co-transporter-2 inhibitors, and glucagon-like peptideย โ€ฆ
  255. Ethnic difference in the pharmacodynamicsโ€efficacy relationship of dipeptidyl peptidaseโ€4 inhibitors between Japanese and nonโ€Japanese patients: a systematicย โ€ฆ
  256. Use of dipeptidyl peptidase 4 inhibitors and fracture risk compared to use of other antiโ€hyperglycemic drugs
  257. Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other secondโ€and thirdโ€line antidiabetic drugs in patients with type 2 diabetes
  258. The effect of metformin or dipeptidyl peptidase 4 inhibitors on clinical outcomes in metastatic nonโ€small cell lung cancer treated with immune checkpoint inhibitors
  259. Effect of dipeptidyl peptidaseโ€4 inhibitors on complement activation
  260. Protective effect of dipeptidyl peptidase-4 inhibitors in testicular torsion/detorsion in rats: a possible role of HIF-1ฮฑ and nitric oxide
  261. Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease
  262. Effects of dipeptidyl peptidase-4 inhibitors on hyperglycemia and blood cyclosporine levels in renal transplant patients with diabetes: a pilot study
  263. Restoration of the insulinotropic effect of glucoseโ€dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidaseโ€4 inhibitors
  264. Dipeptidyl peptidase-4 inhibitors and cardiovascular risks in patients with pre-existing heart failure
  265. Safety and effectiveness of dipeptidyl peptidase-4 inhibitors versus intermediate-acting insulin or placebo for patients with type 2 diabetes failing two oralย โ€ฆ
  266. Pharmacovigilance study of the association between dipeptidyl peptidaseโ€“4 inhibitors and angioedema using the FDA Adverse Event Reporting Systemย โ€ฆ
  267. Molecular docking study on dipeptidyl peptidase-4 inhibitors
  268. No increased risk of hospitalization for heart failure for patients treated with dipeptidyl peptidase-4 inhibitors in Taiwan
  269. Efficacy of glucagonโ€like peptideโ€1 receptor agonists compared to dipeptidyl peptidaseโ€4 inhibitors for the management of type 2 diabetes: A metaโ€analysis ofย โ€ฆ
  270. 3D-QSAR studies of dipeptidyl peptidase-4 inhibitors using various alignment methods
  271. Safety of dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
  272. Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis ofย โ€ฆ
  273. Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in patients with type 2 diabetes mellitus
  274. Association of adverse respiratory events with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors among patients with type 2ย โ€ฆ
  275. Headโ€toโ€head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury
  276. Exposure to dipeptidylโ€peptidase 4 inhibitors and the risk of pneumonia among people with type 2 diabetes: retrospective cohort study and metaโ€analysis
  277. โ€ฆย of hospitalization for heart failure, kidney disease and death with sodiumโ€glucose coโ€transporterโ€2 inhibitors compared with dipeptidyl peptidaseโ€4 inhibitors in type 2ย โ€ฆ
  278. Pharmacogenetics of dipeptidyl peptidase 4 inhibitors in a Taiwanese population with type 2 diabetes
  279. Trends in antidiabetic prescription patterns in Japan from 2005 to 2011 Impact of the introduction of dipeptidyl peptidase-4 inhibitors
  280. Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis
  281. Potential for combination of dipeptidyl peptidaseโ€4 inhibitors and sodiumโ€glucose coโ€transporterโ€2 inhibitors for the treatment of type 2 diabetes
  282. No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidaseโ€4 inhibitors vs therapeutic alternatives
  283. A safety and tolerability profile comparison between dipeptidyl peptidase-4 inhibitors and sulfonylureas in diabetic patients: A systematic review and meta-analysis
  284. Comparative cardiovascular risks of dipeptidyl peptidase-4 inhibitors: analyses of real-world data in Korea
  285. Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus
  286. Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus
  287. Dipeptidyl peptidase-4 inhibitors in progressive kidney disease
  288. Identification of levomenthol derivatives as potential dipeptidyl peptidase-4 inhibitors: a comparative study with gliptins
  289. The roles of dipeptidyl peptidase-4 inhibitors in prognosis of COVID-19 infection in patients with type 2 diabetes mellitus
  290. Association between dipeptidyl peptidase-4 inhibitors and risk of bullous pemphigoid in patients with type 2 diabetes: a population-based cohort study
  291. Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes
  292. Action of dipeptidyl peptidaseโ€4 inhibitors on SARSโ€CoVโ€2 main protease
  293. A fluorescent switchable AIE probe for selective imaging of dipeptidyl peptidase-4 in vitro and in vivo and its application in screening DPP-4 inhibitors
  294. Dipeptidyl peptidase-4 inhibitors for the potential treatment of brain disorders; a mini-review with special focus on linagliptin and stroke
  295. Effect of dipeptidyl peptidase-4 inhibitors on the risk of bone fractures in a Korean population
  296. Use of dipeptidyl peptidase-4 inhibitors and new-onset rheumatoid arthritis in patients with type 2 diabetes
  297. Influence of dipeptidyl peptidase-4 inhibitors on glycemic variability in patients with type 2 diabetes: A meta-analysis of randomized controlled trials
  298. Real-world adherence, persistence, and in-class switching during use of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis involving 594,138ย โ€ฆ
  299. Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes: a system reviewย โ€ฆ
  300. Dipeptidyl Peptidase-4 Inhibitors and the Risk of Heart Failure: Regression to the Truth?
  301. Dipeptidyl peptidase-4 inhibitors and the risk of acute pancreatitis in patients with type 2 diabetes in Taiwan: a population-based cohort study
  302. Caveolin-1, a binding protein of CD26, is essential for the anti-inflammatory effects of dipeptidyl peptidase-4 inhibitors on human and mouse macrophages
  303. Adherence, persistence, and health care costs for patients receiving dipeptidyl peptidase-4 inhibitors
  304. โ€ฆย risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide populationย โ€ฆ
  305. Licochalcone A Derivatives as Selective Dipeptidyl Peptidase 4 Inhibitors with Anti-Inflammatory Effects
  306. Dipeptidyl peptidase-4 inhibitors as new tools for cardioprotection
  307. Structureโ€“activity relationship analysis of cocrystallized gliptin-like pyrrolidine, trifluorophenyl, and pyrimidine-2, 4-dione dipeptidyl peptidase-4 inhibitors
  308. Effect of dipeptidyl peptidase-4 inhibitors on plasma adiponectin: A systematic review and meta-analysis of randomized controlled trials
  309. Factors contributing to the adverse drug reactions associated with the dipeptidyl peptidase-4 (DPP-4) inhibitors: A scoping review
  310. Dipeptidyl peptidase-4 inhibitors and their effects on the cardiovascular system
  311. Dipeptidyl Peptidase-4 inhibitors use in type II diabetic patients in a tertiary hospital
  312. Virtual screening of dipeptidyl peptidase-4 inhibitors using quantitative structureโ€“activity relationship-based artificial intelligence and molecular docking of hitย โ€ฆ
  313. Switching dipeptidyl peptidase-4 inhibitors to tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2 improve arterial stiffness evaluated by cardio-ankleย โ€ฆ
  314. Assessment of the risk of hospitalization for heart failure with dipeptidyl peptidase-4 inhibitors, saxagliptin, alogliptin, and sitagliptin in patients with type 2 diabetesย โ€ฆ
  315. Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients withย โ€ฆ
  316. The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety
  317. Comparative renal effects of dipeptidyl peptidase-4 inhibitors and sodium-glucose cotransporter 2 inhibitors on individual outcomes in patients with type 2ย โ€ฆ
  318. Effect of dipeptidyl-peptidase-4 inhibitors on C-reactive protein in patients with type 2 diabetes: a systematic review and meta-analysis
  319. Efficacy and safety of dipeptidyl peptidaseโ€4 inhibitors as an addโ€on to insulin treatment in patients with type 2 diabetes: a review
  320. Effect of resveratrol on dipeptidyl peptidase-4 inhibitors pharmacokinetics: An in vitro and in vivo approach
  321. Efficacy and safety of Dipeptidyl Peptidase-4 Inhibitors in kidney transplant recipients with Post-transplant diabetes mellitus (PTDM)-a systematic review and Metaย โ€ฆ
  322. Context-dependent effects of dipeptidyl peptidase 4 inhibitors
  323. Effect of dipeptidyl peptidase-4 inhibitors on circulating tumor necrosis factor-ฮฑ concentrations: a systematic review and meta-analysis of controlled trials
  324. Dipeptidyl peptidaseโ€4 inhibitors as preferable oral hypoglycemic agents in terms of treatment satisfaction: results from a multicenter, 12โ€week, open labelย โ€ฆ
  325. Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series
  326. Enzymatic release of dipeptidyl peptidaseโ€4 inhibitors (gliptins) from pigeon pea (Cajanus cajan) nutrient reservoir proteins: In silico and in vitro assessments
  327. Dipeptidyl peptidase-4 inhibitors (DPP-4i) combined with vitamin D3: An exploration to treat new-onset type 1 diabetes mellitus and latent autoimmune diabetes inย โ€ฆ
  328. Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asiaย โ€ฆ
  329. Costโ€“utility analysis of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn basal insulin as addย โ€ฆ
  330. โ€ฆย reduction in chronic kidney disease progression with sodiumโ€glucose cotransporterโ€2 inhibitors compared to dipeptidyl peptidaseโ€4 inhibitors in adults with type 2ย โ€ฆ
  331. Association of dipeptidyl peptidase 4 inhibitors with risk of metastases in patients with type 2 diabetes and breast, prostate or digestive system cancer
  332. Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors
  333. Dipeptidyl peptidase-4 inhibitors and bone metabolism: is vitamin D the link?
  334. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin
  335. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors
  336. Effect of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase 4 inhibitors on cardiovascular function in patients with type 2 diabetes mellitusย โ€ฆ
  337. โ€ฆย treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohortย โ€ฆ
  338. โ€ฆย -Product-Derived 2-Phenyl-3,4-dihydro-2H-benzo[f]chromen-3-amine Analogs as Novel and Potent Dipeptidyl Peptidase 4 (DPP-4) Inhibitors for the Treatment ofย โ€ฆ
  339. Dipeptidyl peptidase-4 inhibitors have adverse effects for the proliferation of human T cells
  340. Association between dipeptidyl peptidaseโ€4 inhibitors and urinary tract infection in elderly patients: A retrospective cohort study
  341. Dipeptidyl peptidase 4 inhibitors attenuate cardiac ischaemiaโ€“reperfusion injury in rats with diabetes mellitus type 2
  342. Incorporating incretin-based therapies into clinical practice: differences between glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors
  343. Re-evaluation of dipeptidyl peptidase-4 inhibitors in patients with heart failure and diabetes mellitus
  344. Myocardial infarction in type 2 diabetes using sodiumโ€“glucose co-transporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 receptorย โ€ฆ
  345. Predicting efficacy of dipeptidyl peptidaseโ€4 inhibitors in patients with type 2 diabetes: association of glycated hemoglobin reduction with serum eicosapentaenoicย โ€ฆ
  346. Cardiovascular outcomes of dipeptidyl peptidase-4 inhibitors in elderly patients with type 2 diabetes: a nationwide study
  347. Dipeptidyl peptidase-4 inhibitors are associated with improved left ventricular diastolic function after acute myocardial infarction in diabetic patients
  348. Meta-analysis of the cardiovascular outcomes with dipeptidyl peptidase 4 inhibitors: validation of the current FDA mandate
  349. Discovery of novel 1, 3, 5-triazine-thiazolidine-2, 4-diones as dipeptidyl peptidase-4 inhibitors with antibacterial activity targeting the S1 pocket for the treatment of typeย โ€ฆ
  350. Treatment discontinuation and clinical events in type 2 diabetes patients treated with dipeptidyl peptidase-4 inhibitors or NPH insulin as third-line therapy
  351. Choosing dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter-2 inhibitors, or both, as add-ons to metformin: patient baseline characteristics are crucial
  352. Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues usingย โ€ฆ
  353. Dipeptidyl peptidase 4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus
  354. Bicyclic cyanothiazolidines as novel dipeptidyl peptidase 4 inhibitors
  355. Renoprotective effect of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus
  356. Dipeptidyl peptidase-4 inhibitors and sulfonylureas prevent the progressive impairment of the nigrostriatal dopaminergic system induced by diabetes during aging
  357. Beneficial effects of dipeptidyl peptidase-4 inhibitors on heart failure with preserved ejection fraction and diabetes
  358. Dipeptidyl peptidase 4 inhibitors and risk of inflammatory bowel disease among patients with type 2 diabetes: a meta-analysis of randomized controlled trials
  359. Dipeptidyl peptidaseโ€4 inhibitors and the risk of communityโ€acquired pneumonia in patients with type 2 diabetes
  360. Acarbose with comparable glucose-lowering but superior weight-loss efficacy to dipeptidyl peptidase-4 inhibitors: a systematic review and network metaย โ€ฆ
  361. Increased risk of hospitalization for heart failure with newly prescribed dipeptidyl peptidase-4 inhibitors and pioglitazone using the Korean Health Insuranceย โ€ฆ
  362. โ€ฆย patients with type 2 diabetes after percutaneous coronary intervention and treated with sodiumโ€“glucose cotransporter 2 inhibitors vs. dipeptidyl peptidase-4 inhibitors
  363. Dipeptidyl peptidase-4 inhibitors in diverse patient populations with type 2 diabetes
  364. Finding the most cost-effective option from commonly used Dipeptidyl peptidase-4 inhibitors in India: a systematic study
  365. Clinical utility of dipeptidyl peptidase-4 inhibitors: a descriptive summary of current efficacy trials
  366. Dipeptidyl peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus
  367. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists
  368. Real-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors
  369. Prior treatment with dipeptidyl peptidase 4 inhibitors is associated with better functional outcome and lower in-hospital mortality in patients with type 2 diabetesย โ€ฆ
  370. Clinical characteristics of the responders to dipeptidyl peptidase-4 inhibitors in Korean subjects with type 2 diabetes
  371. Dipeptidyl peptidase-4 inhibitors and the risk of pancreatitis in patients with type 2 diabetes mellitus: a population-based cohort study
  372. Effect of dipeptidyl peptidase-4 inhibitors on cisplatin-induced acute nephrotoxicity in cancer patients with diabetes mellitus: A retrospective study
  373. Quality-of-life comparison of dapagliflozin versus dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes mellitus: A randomized controlled trial (Jย โ€ฆ
  374. โ€ฆย and structureโ€“activity relationship exploration of uracil-based benzoic acid and ester derivatives as novel dipeptidyl Peptidase-4 inhibitors for the treatment of type 2ย โ€ฆ
  375. The assessment of the efficacy of dipeptidyl peptidase-4 inhibitors in patients with glucocorticoid-induced diabetes by continuous glucose monitoring
  376. Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation
  377. Role of dipeptidyl peptidase-4 inhibitors in patients with diabetes infected with coronavirus-19
  378. Lisinopril prevents bullous pemphigoid induced by dipeptidyl peptidase 4 inhibitors via the Mas receptor pathway
  379. Cardiovascular risks associated with dipeptidyl peptidaseโ€4 inhibitors monotherapy compared with other antidiabetes drugs in the Japanese population: a nationwideย โ€ฆ
  380. Effect of dipeptidyl-peptidase 4 inhibitors on circulating oxidative stress biomarkers in patients with type 2 diabetes mellitus
  381. Defining dipeptidyl peptidaseโ€4 inhibitorsโ€related bullous pemphigoid: A singleโ€centre retrospective study
  382. Non-Specific Inhibition of Dipeptidyl Peptidases 8/9 by Dipeptidyl Peptidase 4 Inhibitors Negatively Affects Mesenchymal Stem Cell Differentiation
  383. Dipeptidyl peptidase-4 inhibitors versus other antidiabetic drugs added to metformin monotherapy in diabetic retinopathy progression: a real world-basedย โ€ฆ
  384. Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes
  385. The efficacy and safety of dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus patients with severe renal impairment: a meta-analysis
  386. Cardiovascular safety signals with dipeptidyl peptidaseโ€4 inhibitors: A disproportionality analysis among highโ€risk patients
  387. Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) agonists: no
  388. Dipeptidyl Peptidase-4 Inhibitors and Inflammation: Dpp-4 Inhibitors Improve Mean Pleatelet Volume and Gamma Glutamyl Transferase Level
  389. Effect of switching to teneligliptin from other dipeptidyl peptidaseโ€4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidneyย โ€ฆ
  390. The effects of dipeptidyl peptidase-4 inhibitors in treatment of obese patients with type 2 diabetes
  391. Dipeptidyl-peptidase-4 inhibitors in type 2 diabetes and COVID-19: from a potential repurposed agent to a useful treatment option
  392. Sodiumโ€glucose coโ€transporterโ€2 inhibitors versus dipeptidyl peptidaseโ€4 inhibitors and the risk of heart failure: A nationwide cohort study of older adults withย โ€ฆ
  393. Lessons learned from cardiovascular outcome clinical trials with dipeptidyl peptidase 4 (DPP-4) inhibitors
  394. Evaluation of treatment satisfaction, efficacy and safety of dipeptidyl peptidase-4 inhibitors in geriatric patients with type 2 diabetes mellitus: A crossย โ€ฆ
  395. Comparative effects of metformin and dipeptidyl peptidase-4 inhibitors in japanese obese patients with type 2 diabetes: a claims database study
  396. Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus
  397. Pharmacoeconomic evaluation of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus: a systematic literature review
  398. Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
  399. โ€ฆย risk factors between patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors: a meta-analysis
  400. The role of dipeptidyl peptidase-4 inhibitors
  401. The effects of dipeptidyl peptidase 4 inhibitors on renal function in patients with type 2 diabetes mellitus
  402. Persistent whole day meal effects of three dipeptidyl peptidaseโ€4 inhibitors on glycaemia and hormonal responses in metforminโ€treated type 2 diabetes
  403. Factors associated with switching from sulphonylureas to dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in the United States
  404. Cardiovascular safety of empagliflozin versus dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes: systematic literature review and indirectย โ€ฆ
  405. Cardiovascular outcomes associated with prescription of sodiumโ€glucose coโ€transporterโ€2 inhibitors versus dipeptidyl peptidaseโ€4 inhibitors in patients with diabetesย โ€ฆ
  406. Lower COVID-19 mortality in patients with type 2 diabetes mellitus taking dipeptidyl peptidase-4 inhibitors: results from a Turkish nationwide study
  407. Comparison of the effects on cardiovascular events between use of metformin and dipeptidyl peptidase-4 inhibitors as the first-line hypoglycaemic agents inย โ€ฆ
  408. A multi-center retrospective analysis examining the effect of dipeptidyl peptidase-4 inhibitors on progression-free survival in patients with prostate cancer
  409. Comparisons between dipeptidyl peptidase-4 inhibitors and other classes of hypoglycemic drugs using two distinct biomarkers of pancreatic beta-cell functionย โ€ฆ
  410. Real-world comparison of mono and dual combination therapies of metformin, sulfonylurea, and dipeptidyl peptidase-4 inhibitors using a common data modelย โ€ฆ
  411. Discovery of potent, selective, and orally bioavailable pyridone-based dipeptidyl peptidase-4 inhibitors
  412. Potential anti-atherosclerotic effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus
  413. Incretinโ€based treatment of type 2 diabetes: glucagonโ€like peptideโ€1 receptor agonists and dipeptidyl peptidaseโ€4 inhibitors
  414. โ€ฆย Adding Sodiumโ€“Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Studyย โ€ฆ
  415. Play of chance versus concerns regarding dipeptidyl peptidase-4 inhibitors: heart failure and diabetes
  416. Changes in medication adherence and unused drugs after switching from daily dipeptidyl peptidase-4 inhibitors to once-weekly trelagliptin in patients with type 2ย โ€ฆ
  417. Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors
  418. Association between use of dipeptidyl peptidase-4 inhibitors and the risk of acute kidney injury: a nested case-control study
  419. โ€ฆย making framework for medicine purchasing in Chinese public hospital decision-making: determining the value of five dipeptidyl peptidase 4 (DPP-4) inhibitors
  420. Synthesis and biological evaluation of novel benzyl-substituted (S)-phenylalanine derivatives as potent dipeptidyl peptidase 4 inhibitors
  421. Systematic review and meta-analysis: dipeptidyl peptidase-4 inhibitors and rheumatoid arthritis risk
  422. Structure-based virtual screening of dipeptidyl peptidase 4 inhibitors and their in vitro analysis
  423. The effects of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 receptor agonists on cognitive functions in adults with type 2 diabetes mellitus: a systematicย โ€ฆ
  424. Tissue distribution of teneligliptin in rats and comparisons with data reported for other dipeptidyl peptidaseโ€4 inhibitors
  425. The effects of switching from dipeptidyl peptidase-4 Inhibitors to Glucagon-Like Peptide-1 receptor agonists on bone mineral density in diabetic patients
  426. Sodium-Glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors, and risk of hospitalization
  427. Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidaseโ€4 inhibitors: Real world evidence fromย โ€ฆ
  428. The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study
  429. Systematic review and meta-analysis of efficacy and safety of combinational therapy with metformin and dipeptidyl peptidase-4 inhibitors
  430. Dipeptidyl peptidase-4 (DPP-4) inhibitors
  431. Risk of hospitalization with sodiumโ€glucose cotransporterโ€2 inhibitors versus dipeptidyl peptidaseโ€4 inhibitors in patients with type 2 diabetes lacking evidence ofย โ€ฆ
  432. Differential effects of thiazolidinediones and dipeptidyl peptidase-4 inhibitors on insulin resistance and ฮฒ-cell function in type 2 diabetes mellitus: a propensityย โ€ฆ
  433. Efficacy and safety of switching to teneligliptin in patients with type 2 diabetes inadequately controlled with dipeptidyl peptidase-4 inhibitors: a 12-week interimย โ€ฆ
  434. Sodium-glucose cotransporter 2 (SGLT2) inhibitors vs. dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset dementia: a propensity score-matchedย โ€ฆ
  435. โ€ฆย preservation, comparing patients receiving sodiumโ€glucose coโ€transporterโ€2 inhibitors with those receiving dipeptidyl peptidaseโ€4 inhibitors, using a supervisedย โ€ฆ
  436. โ€ฆย co-transporter 2 inhibitors may change the development of urinary tract and hematological malignancies as compared with dipeptidyl peptidase-4 inhibitorsย โ€ฆ
  437. Review on the effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non-alcoholic fatty liver disease
  438. โ€ฆย epidemiology of ketosis and low bicarbonate concentration in inpatients treated with sodium-glucose linked cotransporter inhibitors or dipeptidyl peptidase-4 inhibitors
  439. An updated systematic review and meta-analysis on the efficacy and tolerability of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes with moderate toย โ€ฆ
  440. Renoprotection provided by dipeptidyl peptidase-4 inhibitors in combination with angiotensin receptor blockers in patients with type 2 diabetic nephropathy
  441. Use of dipeptidyl peptidase-4 inhibitors is associated with a lower risk of rheumatoid arthritis in patients with type 2 diabetes mellitus: A systematic review and metaย โ€ฆ
  442. Factors related to the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis focusing on ethnicity and study regions
  443. Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Labelย โ€ฆ
  444. Urate-lowering effects of dipeptidyl peptidase-4 inhibitors
  445. Effect of switching from linagliptin to teneligliptin dipeptidyl peptidase-4 inhibitors in older patients with type 2 diabetes mellitus
  446. Association of Dipeptidyl Peptidase-4 Inhibitors Use with Reduced Risk of Hepatocellular Carcinoma in Type 2 Diabetes Patients with Chronic HBV Infection
  447. Dipeptidyl Peptidase-4 Inhibitors and Cardiovascular Outcome
  448. Costโ€effectiveness of sodiumโ€glucose cotransporterโ€2 inhibitors versus dipeptidyl peptidaseโ€4 inhibitors among patients with type 2 diabetes with and withoutย โ€ฆ
  449. Comparing treatment intensification and clinical outcomes of metformin and dipeptidyl peptidaseโ€4 inhibitors in treatmentโ€naรฏve patients with type 2 diabetes in Japan
  450. โ€ฆย rosiglitazoneโ€™s black box warning and restricted access program on the uptake of thiazolidinediones and dipeptidyl peptidase-4 inhibitors among patients with type 2ย โ€ฆ
  451. Sodiumโ€glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on newโ€onset overall cancer in Type 2 diabetes mellitus: A populationโ€based study
  452. Dipeptidyl peptidaseโ€4 inhibitors and prevention of bone fractures: Effects beyond glyemic control
  453. โ€ฆย patients with type 2 diabetes mellitus who do not respond to incretin-based therapies including glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors
  454. Risk heterogeneity of bullous pemphigoid among dipeptidyl peptidaseโ€4 inhibitors: A populationโ€based cohort study using Japanese Latterโ€Stage Elderly Healthcareย โ€ฆ
  455. Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, and Sodium-Glucose Cotransporter-2 Inhibitors and COVID-19 Outcomes
  456. Association of Genetic Variants of HLA-DQA1 with Bullous Pemphigoid Induced by Dipeptidyl Peptidase-4 Inhibitors
  457. Effect of Dipeptidyl Peptidase-4 Inhibitors on Cardiovascular Outcome and Cardiac Function in Patients With Diabetes and Heart Failureโ€•Insights From the Ibarakiย โ€ฆ
  458. Impact of metformin use on the cardiovascular effects of dipeptidyl peptidaseโ€4 inhibitors: An analysis of Medicare claims data from 2007 to 2015
  459. Synthesis and biological evaluation of pyrrolidine-2-carbonitrile and 4-fluoropyrrolidine-2-carbonitrile derivatives as dipeptidyl peptidase-4 inhibitors for the treatmentย โ€ฆ
  460. Design, synthesis, and pharmacological evaluation of highly potent and selective dipeptidyl peptidaseโ€4 inhibitors
  461. Effect of Dipeptidyl Peptidase-4 Inhibitors vs. Metformin on Major Cardiovascular Events Using Spontaneous Reporting System and Real-World Database Study
  462. Pemphigoid nodularis induced by long-term use of dipeptidyl peptidase-4 inhibitors
  463. Head-to-Head comparison of the hypoglycemic efficacy and safety between dipeptidyl peptidase-4 inhibitors and ฮฑ-glucosidase inhibitors in patients with typeย โ€ฆ
  464. Dipeptidyl Peptidase 4 Inhibitors and Gallbladder or Biliary Diseases: Data From the US Food and Drug Administration Adverse Event Reporting System
  465. Dipeptidyl peptidase 4 (DPP4) inhibitors stride up the management of Parkinsonโ€™s disease
  466. Dipeptidyl-Peptidase 4 Inhibitors did not Improve Renal Endpoints in Advanced Diabetic Kidney Disease
  467. Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetesโ€”Randomized controlled studyโ€”
  468. Prevalence of diabetes mellitus in bullous pemphigoid patients in the absence of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis
  469. Three ileus cases associated with the use of dipeptidyl peptidaseโ€4 inhibitors in diabetic patients
  470. Dipeptidyl Peptidase-4 Inhibitorsโ€“Emerging Player for Vascular Protectionโ€“
  471. Response to the dipeptidyl peptidaseโ€4 inhibitors in J apanese patients with type 2 diabetes might be associated with a diplotype of two single nucleotideย โ€ฆ
  472. Dynamics of total volume of pancreatic ฮฑโ€and ฮฒโ€cells under the influence sulfonylureas and their combination with dipeptidyl peptidaseโ€4 inhibitors
  473. Association between dipeptidyl peptidase-4 inhibitors and autoimmune disorders: Data mining of the spontaneous reporting system in Japan
  474. Combination therapy of sodiumโ€“glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences
  475. Design, synthesis and evaluation of a series of novel long-acting dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes
  476. Risk of stent failure in patients with diabetes treated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors: A nationwide observationalย โ€ฆ
  477. Observational study on dipeptidyl peptidase-4 inhibitors: a real-life analysis on 360 patients from the ASL VCO territory in Italy
  478. Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes
  479. Comparing sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset depression: a propensity score-matched study inย โ€ฆ
  480. Sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors combination therapy in type 2 diabetes: A systematic review of currentย โ€ฆ
  481. Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies toย โ€ฆ
  482. Impact of standard-dose dipeptidyl peptidase-4 inhibitors on the incidence of graft-versus-host disease after allogeneic hematopoietic cell transplantation
  483. Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis andย โ€ฆ
  484. Can glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors help in mitigating the risk of atrial fibrillation in patients with diabetes?
  485. In vitro metabolism and transport of the new dipeptidyl peptidase 4 inhibitors, KR66222 and KR66223
  486. Impact of dipeptidyl peptidase-4 inhibitors on glycemic control and cardiovascular safety with adherence: an overview
  487. Efficacy, safety and impact on ฮฒ-cell function of dipeptidyl peptidase-4 inhibitors plus metformin combination therapy in patients with type 2 diabetes and theย โ€ฆ
  488. Risk of heart failure with dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
  489. Dipeptidyl peptidase 4 inhibitors
  490. Network meta-analysis of liraglutide versus dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes in Japanese patients
  491. Comparative Safety of Dipeptidyl Peptidaseโ€4 Inhibitors and Sudden Cardiac Arrest and Ventricular Arrhythmia: Populationโ€Based Cohort Studies
  492. The use of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes & chronic kidney disease
  493. Reshaping diabetes care: the fundamental role of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists in clinical practice
  494. Determination of dipeptidyl peptidase-4 inhibitors by spectrophotometric and chromatographic methods
  495. โ€ฆย with diabetes after peripheral artery disease revascularization treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors
  496. Shortโ€term and longโ€term effects of dipeptidyl peptidaseโ€4 inhibitors in type 2 diabetes mellitus patients with renal impairment: a metaโ€analysis of randomizedย โ€ฆ
  497. All-cause mortality of insulin plus dipeptidyl peptidase-4 inhibitors in persons with type 2 diabetes
  498. The roles of dipeptidyl peptidase 4 (DPP4) and DPP4 inhibitors in different lung diseases: new evidence
  499. New dipeptidyl peptidase 4 inhibitors among adamantane derivatives
  500. An update in incretin-based therapy: a focus on dipeptidyl peptidase-4 inhibitors
  501. Comparing adoption of breakthrough and โ€œme-tooโ€ drugs among Medicare beneficiaries: a case study of dipeptidyl peptidase-4 inhibitors
  502. Dipeptidyl peptidaseโ€4 inhibitors are effective in J apanese type 2 diabetic patients with sustained endogenous insulinโ€secreting capacity, a higher body mass indexย โ€ฆ
  503. Association of the gallbladder or biliary diseases with dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: a meta-analysis of randomizedย โ€ฆ
  504. Outcomes for inappropriate renal dose adjustment of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: population-based study
  505. Dipeptidyl peptidase 4 inhibitors linked bullous pemphigoid in patients with type 2 diabetes mellitus: A series of 13 cases
  506. Benzimidazole-based dual dipeptidyl peptidase-4 and xanthine oxidase inhibitors
  507. Effect of dipeptidyl peptidase 4 inhibitors used in combination with insulin treatment in patients with type 2 diabetes: a systematic review and meta-analysis
  508. Dipeptidyl peptidaseโ€4 inhibitors and aerobic exercise synergistically protect against liver injury in ovariectomized rats
  509. Managing hyperglycemia in patients with type 2 diabetes mellitus: rationale for the use of dipeptidyl peptidase-4 inhibitors in combination with other oralย โ€ฆ
  510. Switching from premixed insulin to basal insulin analogue for type 2 diabetes and role of dipeptidyl peptidase-4 inhibitors
  511. Do Dipeptidyl Peptidase-4 Inhibitors Increase the Risk of Heart Failure in Patients with Type 2 Diabetes?
  512. โ€ฆย Synthesis, Biological Evaluation, and Docking Studies of (S)โ€Phenylalanine Derivatives with a 2โ€Cyanopyrrolidine Moiety as Potent Dipeptidyl Peptidase 4 Inhibitors
  513. The Potential of some Plant Extracts as Radical Scavengers and Dipeptidyl Peptidase-4 Inhibitors
  514. The risk of acute pancreatitis after initiation of dipeptidyl peptidase 4 inhibitors: testing a hypothesis of subgroup differences in older US adults
  515. Cardiovascular effectiveness of glucagon-like peptide 1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes: A meta-analysis based onย โ€ฆ
  516. Bullous Pemphigoid Associated With Dipeptidyl Peptidase-4 Inhibitors: A Case Report and Review of Current Evidence
  517. Dipeptidyl peptidase-4 inhibitors as add-on therapy to insulin: rationale and evidences
  518. Safety, effectiveness, and cost of dipeptidyl peptidase-4 inhibitors versus intermediate acting insulin for type 2 diabetes: protocol for a systematic review andย โ€ฆ
  519. Predictors of the efficacy of dipeptidyl peptidase-4 inhibitors in Taiwanese patients with type 2 diabetes mellitus
  520. Understanding the Role of Dipeptidyl Peptidase-4 Inhibitors in COVID-19: Findings From a Systematic Review
  521. โ€ฆย prescribing and utilization trends of diabetes medications among patients with renal impairment: emerging role of linagliptin and other dipeptidyl peptidase 4 inhibitors
  522. Phytochemical content and the potential of Punica granatum peel extracts as radical scavengers and dipeptidyl peptidase-4 inhibitors
  523. Clinical analysis of pre-existing diabetes mellitus and dipeptidyl peptidase-4 inhibitors in patients with remitting seronegative symmetrical synovitis and pitting edemaย โ€ฆ
  524. Design, synthesis and anti-diabetic activity of piperazine sulphonamide derivatives as dipeptidyl peptidase-4 inhibitors
  525. Dipeptidyl peptidase 4 inhibitors and risk of inflammatory bowel disease: real-world evidence in US adults
  526. โ€ฆย โ€CoVโ€2 vaccineโ€triggered conversion from systemic lupus erythematosus (SLE) to bullous SLE and dipeptidyl peptidase 4 inhibitorsโ€associated bullous pemphigoid
  527. โ€ฆย effects of second-line drugs in Japanese patients with type 2 diabetes mellitus: Analysis of claims data for metformin and dipeptidyl peptidase-4 inhibitors as the firstย โ€ฆ
  528. Structure-based De Novo Design and Docking Studies of 5 (S)-Methyl-LProline Containing Peptidomimetic Compounds as Dipeptidyl Peptidase-4 Inhibitors
  529. Real-world evaluation of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors for managing type 2 diabetes mellitus: aย โ€ฆ
  530. Association between dipeptidyl peptidase-4 inhibitors and allergic rhinitis in Asian patients with diabetes
  531. Dipeptidylโ€peptidase (DPP)โ€4 inhibitors and glucagonโ€like peptide (GLP)โ€1 analogues for prevention or delay of type 2 diabetes mellitus and its associatedย โ€ฆ
  532. Heterogeneous Treatment Effects on Cardiovascular Diseases With Dipeptidyl Peptidaseโ€4 Inhibitors Versus Sulfonylureas in Type 2 Diabetes Patients
  533. Dipeptidyl peptidase-4 inhibitors: sensitivity markers
  534. Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: evaluation of clinical course and treatment response
  535. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists: a review for the general cardiologist
  536. Association between dipeptidyl peptidaseโ€4 inhibitors and increased risk for bullous pemphigoid within 3 months from first use: A 5โ€year populationโ€based cohortย โ€ฆ
  537. Dipeptidyl peptidaseโ€4 inhibitors and heart failure exacerbation in the veteran population: an observational study
  538. Potential cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: current evidence and ongoing trials
  539. Effects of Dipeptidyl Peptidase-4 Inhibitors and Sulfonylureas on Cognitive and Physical Function in Nursing Home Residents
  540. Dipeptidyl peptidase-4 inhibitors and the ischemic heart: additional benefits beyond glycemic control
  541. Comprehensive efficacy of ipragliflozin on various conditioned type 2 diabetes compared with dipeptidyl peptidase-4 inhibitors and with both agents, based on a realย โ€ฆ
  542. Comparison of different case-crossover variants in handling exposure-time trend or persistent-user bias: using dipeptidyl peptidase-4 inhibitors and the risk ofย โ€ฆ
  543. Comparative effects of sulphonylureas, dipeptidyl peptidaseโ€4 inhibitors and sodiumโ€glucose coโ€transporterโ€2 inhibitors added to metformin monotherapy: aย โ€ฆ
  544. Demographic and clinical characteristics of patients with type 2 diabetes mellitus initiating dipeptidyl peptidase 4 inhibitors: a retrospective study of UKย โ€ฆ
  545. Design, synthesis, and biological evaluation of triazolopiperazine-based ฮฒ-amino amides as potent, orally active dipeptidyl peptidase IV (DPP-4) inhibitors
  546. Design and synthesis of 3-pyridylacetamide derivatives as dipeptidyl peptidase IV (DPP-4) inhibitors targeting a bidentate interaction with Arg125
  547. Healthcare costs of the combination of metformin/dipeptidyl peptidase-4 inhibitors compared with metformin/other oral antidiabetes agents in patients with type 2ย โ€ฆ
  548. โ€ฆย trials of sodium glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor analogues and dipeptidyl peptidase-4 inhibitors to a representativeย โ€ฆ
  549. Effect of dipeptidyl peptidase-4 inhibitors on glycated hemoglobin levels relies on dietary sodium intake
  550. New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: A Chinese population-basedย โ€ฆ
  551. โ€ฆย drugs and drug costs among residents of long-term care facilities under a bundled payment system: Case studies of dipeptidyl peptidase-4 inhibitors and direct oralย โ€ฆ
  552. Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes
  553. Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors vs. Dipeptidyl Peptidase-4 Inhibitors in Frail People With Diabetes Who Were Recentlyย โ€ฆ
  554. Use of dipeptidyl peptidaseโ€4 inhibitors and risk of splanchnic vein thrombosis: a Danish nationwide newโ€user active comparator cohort study
  555. Similarity and dissimilarity in antinociceptive effects of dipeptidyl-peptidase 4 inhibitors, Diprotin A and vildagliptin in rat inflammatory pain models following spinalย โ€ฆ
  556. Synthesis and biological evaluation of azobicyclo [3.3. 0] octane derivatives as dipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes
  557. Cardiovascular and Renal Outcomes With Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors Combination Therapy: A Meta-Analysis ofย โ€ฆ
  558. Improvement in mortality and end-stage renal disease in patients with type 2 diabetes after acute kidney injury who are prescribed dipeptidyl peptidase-4 inhibitors
  559. Synthesis and biological evaluation of bicyclo [3.3. 0] octane derivatives as dipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes
  560. Acquired hemophilia A associated with dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus: a single-center case series in Japan
  561. Risk of cardiovascular events associated with dipeptidyl peptidase-4 inhibitors in patients with diabetes with and without chronic kidney disease: A nationwideย โ€ฆ
  562. Vilsmeier reagent initialed sequential one-pot multicomponent synthesis of N, O-disubstituted glycolamides as dipeptidyl peptidase 4 inhibitors
  563. โ€ฆย with newer agents used to treat type 2 diabetes (T2DM) in the United States: canagliflozin versus dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptideย โ€ฆ
  564. Comparative risk for cardiovascular diseases of dipeptidyl peptidase-4 inhibitors vs. sulfonylureas in combination with metformin: results of a two-phase study
  565. Design, synthesis and anti-diabetic activity of novel 1, 2, 3-triazole-5-carboximidamide derivatives as dipeptidyl peptidase-4 inhibitors
  566. Dipeptidyl Peptidase-4 Inhibitors
  567. Association between dipeptidyl peptidase-4 inhibitors use and leptin in type 2 diabetes mellitus
  568. Cardiovascular outcomes of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes on insulin therapy
  569. Clinical review: Safety and efficacy comparison between sulfonylureas and dipeptidyl peptidase-4 inhibitors as second-line therapies in type 2 diabetes mellitus
  570. Use of dipeptidyl peptidaseโ€4 inhibitors and the risk of arthralgia: Populationโ€based cohort and nested caseโ€“control studies
  571. Risk of myocardial infarction in trials with dipeptidyl peptidase-4 inhibitors: is duration of study a real issue?
  572. Severe hypoglycemia by combination therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors and sulfonylureas
  573. Decreased Mortality After Long-Term Treatment With Dipeptidyl Peptidase-4 Inhibitors: A Retrospective Study of US Veterans With Type 2 Diabetes
  574. Dipeptidyl Peptidase-4 inhibitors and joint pain: a retrospective cohort study of older veterans with type 2 diabetes mellitus
  575. Optimizing the treatment of newly diagnosed type 2 diabetes mellitus with combination of dipeptidyl peptidase-4 inhibitors and metformin: An expert opinion
  576. Potential role of dipeptidyl peptidase-4 inhibitors in atrial fibrillation
  577. Dipeptidyl peptidase-4 inhibitors as a third-line oral antihyperglycaemic agent in patients with type 2 diabetes mellitus: the impact of ethnicity
  578. Treatment Burden on Once-Weekly Omarigliptin Versus Daily Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes: Randomized Controlled Trialย โ€ฆ
  579. Comparison of Efficacy of Dipeptidyl Peptidaseโ€4 Inhibitors and Sodiumโ€Glucose Coโ€Transporter 2 Inhibitors Between Japanese and Nonโ€Japanese Patients: A Metaย โ€ฆ
  580. Design of potent dipeptidyl peptidase IV (DPP-4) inhibitors by employing a strategy to form a salt bridge with Lys554
  581. Dipeptidyl peptidase-4 inhibitors and protection against stroke: A systematic review and meta-analysis
  582. โ€ฆย care management of type 2 diabetes: a comparison of the efficacy and safety of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors
  583. โ€ฆย of ICU Admission and Related Mortality in Patients With Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors: A Territory-Wideย โ€ฆ
  584. Discovery of potential natural dipeptidyl peptidase-4 inhibitors for type-2 diabetes treatment via structure-based virtual screening
  585. Efficacy and safety of switching to teneligliptin in patients with type 2 diabetes inadequately controlled with dipeptidyl peptidase-4 inhibitors: 52-week resultsย โ€ฆ
  586. SVMDLF: A novel Rโ€based Web application for prediction of dipeptidyl peptidase 4 inhibitors
  587. Hemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin with reninโ€“angiotensin system inhibitors in type 2 diabetic patients with albuminuria
  588. โ€ฆย -induced plasma active glucagon-like peptide-1 levels by co-administration of sodiumโ€“glucose cotransporter inhibitors with dipeptidyl peptidase-4 inhibitors inย โ€ฆ
  589. Differences in baseline characteristics between type 2 diabetes mellitus patients treated with dipeptidyl peptidase-4 inhibitors in randomized controlled trials and thoseย โ€ฆ
  590. Efficacy and safety of dipeptidyl peptidase-4 inhibitors: systematic review and meta-analysis
  591. Metformin combined with dipeptidyl peptidase-4 inhibitors or metformin combined with sulfonylureas in patients with type 2 diabetes: a real world analysis of the Southย โ€ฆ
  592. Cardiovascular surrogate markers and cardiometabolic therapeutics: a viewpoint learned from clinical trials on dipeptidyl peptidase-4 inhibitors
  593. Hyperamylasemia is not Associated with Dipeptidyl Peptidase 4 Inhibitors in South Indian Adults with Type 2 Diabetes Mellitus
  594. Comparing the effect of dipeptidyl-peptidase 4 inhibitors and sulfonylureas on albuminuria in patients with newly diagnosed type 2 diabetes mellitus: A prospectiveย โ€ฆ
  595. Concordance with prescribing information dosage recommendations for dipeptidyl-peptidase-4 inhibitors among type 2 diabetes mellitus patients with moderate toย โ€ฆ
  596. Comparative effectiveness of sodium-glucose co-transporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on cardiorenal function and treatment adherence: Aย โ€ฆ
  597. Correction to:โ€œcardiovascular outcomes comparison of dipeptidyl peptidase-4 inhibitors versus sulfonylurea as add-on therapy for type 2 diabetes mellitus: aย โ€ฆ
  598. Effect of Add-On Therapy of Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase 4 Inhibitors on Adipokines in Type 2 Diabetes Mellitus
  599. Economic impact of combining metformin with dipeptidyl peptidase-4 inhibitors in diabetic patients with renal impairment in spanish patients
  600. Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidenceย โ€ฆ
  601. Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs
  602. The dipeptidyl peptidase (DPP)-4 inhibitors for type 2 diabetes mellitus in challenging patient groups
  603. Differential characteristics of type 2 diabetes in the elderly. Role of dipeptidyl peptidase 4 inhibitors
  604. Effect of Dipeptidyl Peptidase-4 Inhibitors on Bone Health in Patients with Type 2 Diabetes Mellitus
  605. SAFETY PROFILE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS.
  606. Discovery of 3H-imidazo [4, 5-c] quinolin-4 (5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors
  607. Dipeptidyl Peptidase 4 Inhibitors and Venous Thromboembolism Risk in Patients with Type 2 Diabetes: A Meta-analysis of Cardiovascular Outcomes Trials
  608. Inhibitors of dipeptidyl peptidaseโ€4 as therapeutic agents for individuals with type 2 diabetes: a 25โ€year journey
  609. Model QSAR Classification Using Conv1D-LSTM of Dipeptidyl Peptidase-4 Inhibitors
  610. Association between therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors and risk of ileus: a cohort study
  611. Effect of dipeptidyl peptidase-4 inhibitors inhibitor on cognitive dysfunction in diabetes: A protocol for systematic review and meta analysis
  612. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus patients with moderate to severe renal impairment: a metaย โ€ฆ
  613. Dipeptidyl peptidase-4 inhibitors and cardiovascular safety
  614. Impact of Switching from Sulfonylureas to Dipeptidyl Peptidase-4 Inhibitors on Hypoglycemia Burden in the United Statesโ€”A Predictive Modeling Approach
  615. Comparative risk of musculoskeletal adverse reactions among new users of dipeptidyl peptidase-4 inhibitors: A retrospective cohort study
  616. โ€ฆย (TECOS) with studyโ€level metaโ€analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidaseโ€4 (DPPโ€4) inhibitors
  617. Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus
  618. Dipeptidyl peptidase-4 inhibitors
  619. Insight in the safety profile of antidiabetic agents glucagonโ€like peptideโ€1 agonists and dipeptidyl peptidaseโ€4 inhibitors in daily practice from the patient perspective
  620. Drug interactions of dipeptidyl peptidase 4 inhibitors involving CYP enzymes and P-gp efflux pump
  621. Healthcare resource utilization after initiation of sodiumโ€glucose coโ€transporterโ€2 inhibitors versus dipeptidyl peptidaseโ€4 inhibitors or other glucoseโ€lowering drugsย โ€ฆ
  622. Comparison of goat and sheep ฮฒ-lactoglobulin to bovine ฮฒ-lactoglobulin as potential source of dipeptidyl peptidase IV (DPP-4) inhibitors
  623. Dipeptidyl peptidase-4 inhibitors do not alter GH/IGF-I axis in adult diabetic patients
  624. Dipeptidyl peptidase 4 inhibitors in routine clinical practice: experiences from a Scottish teaching hospital
  625. Effect of dipeptidyl peptidase-4 inhibitors on fat metabolism in patients with type 2 diabetes mellitus
  626. Cardiovascular outcomes comparison of dipeptidyl peptidase-4 inhibitors versus sulfonylurea as add-on therapy for type 2 diabetes mellitus: a meta-analysis
  627. The role of dipeptidyl peptidase 4 inhibitors in fat metabolism in patients with type 2 diabetes and obesity
  628. Transitioning from insulin to dipeptidyl-peptidase 4 (DPP-4) inhibitors for type 2 diabetes
  629. Acute pancreatitis in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase-4 inhibitors
  630. Dipeptidyl-peptidase 4 inhibitors
  631. โ€ฆย between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with kidney outcomes inย โ€ฆ
  632. Dipeptidyl peptidase-4 inhibitors or sodium glucose co-transporter-2 inhibitors as an add-on to insulin therapy: A comparative review
  633. In Silico approach for screening of the indonesian medicinal plants database to discover potential dipeptidyl peptidase-4 inhibitors
  634. Design, synthesis and SAR studies of novel and potent dipeptidyl peptidase 4 inhibitors
  635. โ€ฆย of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: aย โ€ฆ
  636. Liver injury with dipeptidyl peptidase-4 (DPP-4) inhibitors (GLIPTINS): signals emerging from the US-FDA Adverse Event Reporting System
  637. Comment on โ€œOral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case controlย โ€ฆ
  638. Under-representation of frail older people in meta-analysis of dipeptidyl peptidase-4 inhibitors and hypoglycaemia
  639. Dipeptidyl peptidase-4 inhibitors: Comparative analysis of members of the group
  640. Glial cell type-specific changes in spinal dipeptidyl peptidase 4 expression and effects of its inhibitors in inflammatory and neuropatic pain
  641. โ€ฆย between the use of dipeptidyl peptidase-4 inhibitors (DPP-4i), glucagon-like peptide-1 receptor agonists (GLP-1 RAs), or sodium-glucose cotransporter-2 inhibitors ย โ€ฆ
  642. Clinical characteristics of bullous pemphigoid in elderly patients with type 2 diabetes mellitus: The association with the use of dipeptidyl peptidase-4 inhibitors
  643. The many facets of CD26/dipeptidyl peptidase 4 and its inhibitors in disorders of the CNSโ€“a critical overview
  644. Fracture risk reduction with use of dipeptidyl peptidase-4 inhibitors: is there immortal time bias?
  645. โ€ฆย Effects of Dipeptidyl Peptidase 4 Inhibitors and Glucagon-Like Peptide 1 Agonist-Administered Concomitant with Sodium-Glucose Cotransporter 2 Inhibitorsย โ€ฆ
  646. Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors
  647. Is the popularity of dipeptidyl-peptidase-4 inhibitors justified? Insights from mechanistic studies and clinical trials
  648. โ€ฆย in the pathogenesis of uterine leiomyoma and the promising anti-fibrotic effects of dipeptidyl peptidase-4 and fibroblast activation protein inhibitors in the treatment ofย โ€ฆ
  649. Dynamics of switching, adherence, and persistence of dipeptidyl peptidase-4 inhibitors use: A nationwide cohort study
  650. โ€ฆย hours glucose profile and glycaemic variability evaluated by continuous glucose monitoring in patients with type 2 diabetes receiving dipeptidyl peptidaseโ€4 inhibitors
  651. โ€ฆย Docking Studies of 1โ€(ฮณโ€1,2,3โ€Triazol Substituted Prolyl)โ€(S)โ€3,3โ€Difluoropyrrolidines as a Novel Series of Potent and Selective Dipeptidyl Peptidaseโ€4 Inhibitors
  652. Odds of acute kidney injury in patients receiving dipeptidyl peptidase 4 inhibitors: a national cohort study within the Department of Veterans Affairs
  653. Dynamics of total volume of pancreatic ฮฑโ€and ฮฒโ€cells under the influence sulfonylureas and their combination with dipeptidyl peptidaseโ€4 inhibitors
  654. Comparison of the effects of Teneligliptin and Sitagliptin, Two Dipeptidyl Peptidase 4 Inhibitors with different half-lives, on glucose fluctuation and glucagon-likeย โ€ฆ
  655. Fracture risk reduction with use of dipeptidyl peptidase-4 inhibitors: response to Driessen et al.
  656. Limited Extent of Pleiotropic Effects Mediated by Dipeptidyl Peptidase-4 Inhibitors in Patients With Diabetes Mellitus
  657. Safety of dipeptidyl peptidase-4 inhibitors in Covid-19: an update
  658. Evaluation of largeโ€scale clinical trials on cardiovascular disease risk in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase 4 inhibitors and a newย โ€ฆ
  659. Cluster analysis in prediction of biological activity and molecular structure relationship of dipeptidyl peptidase-4 inhibitors for the type two diabetes mellitus treatment
  660. Dipeptidyl peptidase-4 inhibitors do not increase overall adverse events in type 2 diabetes
  661. Integrated protocol to design potential inhibitors of dipeptidyl peptidase-4 (DPP-4)
  662. Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors
  663. Dipeptidyl peptidase-4 inhibitors use in clinical practice
  664. Drug utilization review of Dipeptidyl Peptidase-4 (DPP-4) inhibitors in Alice Ho Miu Ling Nethersole Hospital (AHNH).
  665. Efficacy of ฮฑโ€glucosidase inhibitors combined with dipeptidylโ€peptidaseโ€4 inhibitor (alogliptin) for glucose fluctuation in patients with type 2 diabetes mellitus byย โ€ฆ
  666. Bullous Drug Reaction with Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
  667. Hypoglycemia in the diabetes treatment-risk minimization with dipeptidyl peptidase-4 inhibitors
  668. A short-term follow-up of glycemic and body weight changes in diabetic patients who replaced dipeptidyl peptidase-4 inhibitors with the sodium-glucose cotransporterย โ€ฆ
  669. Incretin-based Therapies (Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors) for the Treatment of Type 2 Diabetes
  670. Use of dipeptidyl peptidase-4 inhibitors in patients with diabetes
  671. Inclusion of the EXAMINE study in a meta-analysis of the addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia
  672. Dipeptidyl peptidase-4 inhibitors use and relative risk of ischemic cerebrovascular disease in type 2 diabetic patients in a case-control study
  673. B-PO05-144 COMPARING SODIUM GLUCOSE COTRANSPORTER 2 INHIBITORS AND DIPEPTIDYL PEPTIDASE-4 INHIBITORS ON NEW-ONSET ATRIALย โ€ฆ
  674. Association Between Pancreatic Cancer and Dipeptidyl Peptidase-4 Inhibitors Use in a Case-Control Study
  675. โ€ฆย : traditional hypoglycemic agents (metformin, sulfonylureas, thiazolidinediones) versus glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors
  676. Author Correction: Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: A meta-analysis of randomized clinical trials
  677. Design, Synthesis and Biological Evaluation of Novel Imidazolone Derivatives as Dipeptidyl Peptidase 4 Inhibitors
  678. โ€ฆย and pancreatic cancer in sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors: a propensity scoreย โ€ฆ
  679. Dipeptidyl peptidase 4 inhibitors diprotin A and sitagliptin administered on weeks 2-3 of postnatal development modulate monoamine metabolism in the striatum ofย โ€ฆ
  680. Computationally Guided Design of Dipeptidyl Peptidase-4 Inhibitors
  681. Dipeptidyl peptidase-4 inhibitors and risk of venous thromboembolism: data mining of FDA adverse event reporting system
  682. Left Ventricular Size And Function In Patient With Type 2 Diabetes Mellitus Treated With Dipeptidyl Peptidase-4 Inhibitors
  683. Educating patients with type 2 diabetes on a new class of drug, dipeptidyl peptidase 4 inhibitors
  684. Canagliflozin (CANA) added on to dipeptidyl peptidase-4 inhibitors (DPP-4i) or glucagon-like peptide-1 (GLP-1) agonists with or without other antihyperglycemicย โ€ฆ
  685. Research progress of mechanisms through which dipeptidyl peptidase-4 inhibitors regulate glycemia
  686. Benefits of insulin degludec/liraglutide are maintained even in patients discontinuing sulphonylureas or dipeptidyl peptidaseโ€4 inhibitors upon initiation of degludecย โ€ฆ
  687. Scaffold-hopping from xanthines to tricyclic guanines: A case study of dipeptidyl peptidase 4 (DPP4) inhibitors
  688. Benzo[4,5]thieno[2,3โ€d]pyrimidine phthalimide derivative, one of the rare noncompetitive inhibitors of dipeptidyl peptidaseโ€4
  689. Synergistic effect of ฮฑโ€glucosidase inhibitors and dipeptidyl peptidase 4 inhibitor treatment
  690. Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Healthย โ€ฆ
  691. Health economic evaluation of dipeptidyl peptidase-4 inhibitors
  692. Cardiovascular safety of dipeptidyl peptidase-4 (DPP-4) inhibitors
  693. A systematic review on the clinical outcomes of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients
  694. Dipeptidyl peptidase-4 inhibitors in type 2 diabetic elderly patient
  695. Effect of dipeptidyl peptidase 4 inhibitors on cardiovascular events in type-2 diabetes patients with renal impairment: A systematic review and meta-analysis
  696. Discovery of 6-(Aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as Potent, Selective Dipeptidyl Peptidase-4 (DPP4) Inhibitors
  697. โ€ฆย -1-((3aS, 7aS)-octahydro-1H-indol-1-yl)-4-(2, 4, 5-trifluorophenyl) butan-1-one derivatives as potent inhibitors of dipeptidyl peptidase-4: Design, synthesis, biologicalย โ€ฆ
  698. Retracted: Effect of dipeptidyl peptidaseโ€4 inhibitors on the progression of atherosclerosis in patients with type 2 diabetes mellitus: A metaโ€analysis of randomisedย โ€ฆ
  699. Towards evidence-based medicine: large-scale intervention trials with dipeptidyl peptidase-4 inhibitors
  700. Dipeptidyl peptidase-4 inhibitors and heart failure: friends or foes?
  701. Pathogenetic background of dipeptidyl peptidase-4 inhibitors application in the management of diabetes mellitus type 2
  702. Lower risks of sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset non-alcoholic fatty liver diseaseย โ€ฆ
  703. Risk of heart failure and adverse cardiovascular outcomes with dipeptidyl peptidase-4 inhibitors in type 2 diabetic patients: A meta-analysis of randomized controlledย โ€ฆ
  704. Effects of Increasing Metformin Dose vs Adding/Switching to Dipeptidyl Peptidase-4 Inhibitors on Glycemic Control in Patients with Type 2 Diabetes
  705. Sodium Glucose Cotransporter-2 Inhibitors as an Add-on Therapy to Metformin Plus Dipeptidyl Peptidase-4 Inhibitor in Patients with Type 2 Diabetes
  706. Combination therapy with dipeptidyl peptidase-4 and P2X7 purinoceptor inhibitors gives rise to antiepileptic effects in rats
  707. CD26/Dipeptidyl Peptidase-4 Inhibitors as Prophylaxis of Chronic Lung Allograft Dysfunction after Lung Transplantation, a Clinicopathological Evaluation
  708. Dipeptidyl Peptidase-4 Inhibitors and Beta Cell Mass in Japanese Adults with Type 2 Diabetes
  709. The roles of dipeptidyl peptidase-4 and its inhibitors in the regulation of airway epithelial-mesenchymal transition
  710. 1386-P: Dipeptidyl Peptidase-4 Inhibitors and the Risk of Skin Cancer among Patients with Type 2 Diabetesโ€”Population-Based Cohort Study
  711. Progress in dipeptidyl peptidase-4 and its inhibitors
  712. Further possible mechanisms of dipeptidyl peptidase-4 inhibitors to decrease blood glucose in subjects with type 2 diabetes
  713. Candidate Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes
  714. CLINICAL ASPECTS FOR USE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS IN COMBINATION WITH METFORMIN: BENEFITS FOR DIFFERENT GROUPS OFย โ€ฆ
  715. Contemporary trends in prescription of dipeptidyl Peptidase-4 inhibitors in the context of US food and drug administration warnings of heart failure risk
  716. Combined Ligand-Based and Structure-Based Virtual Screening Approach for Identification of New Dipeptidyl Peptidase 4 Inhibitors
  717. The Old and the new in the Treatment of Type 2 Diabetes: Focus on the combination Therapy with Dipeptidyl peptidase-4 Inhibitors and Metformin
  718. EPH54 Cancer Associations with Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)
  719. Effect of Dipeptidyl peptidase-4 inhibitors on the progression of atherosclerosis in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
  720. Sitagliptin and vildagliptin use evaluation among dipeptidyl peptidase 4 inhibitors in adult Koreans with type 2 diabetes mellitus
  721. ฮ’ullous Pemphigoid Associated with Dipeptidyl Peptidase 4 Inhibitors for the Treatment of Type 2 Diabetes: A Multicenter Study in Istanbul
  722. Latent class analysis of patientsโ€™ background factors affecting the risk of specific adverse drug reactions to dipeptidyl peptidase 4 inhibitors.
  723. Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2015; 39: 342-7)
  724. Comment on โ€œOral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-controlย โ€ฆ
  725. Response: Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2015; 39: 342-7)
  726. Dipeptidyl peptidase-4 inhibitors and mortality risks in patients with prostate cancer receiving androgen deprivation therapy: a population-based cohort study
  727. Dipeptidyl Peptidase-4 (DPP4) Inhibitors
  728. Co-medications and dipeptidyl peptidase-4 inhibitors associated bullous pemphigoid,
  729. In type 2 diabetes, dipeptidyl peptidase-4 inhibitors do not increase pancreatitis
  730. Cost and utilization outcomes after exclusion of dipeptidyl peptidase-4 inhibitors and other diabetes drug category changes in a self-funded, state employee managedย โ€ฆ
  731. Erroneous Event Count in a Meta-Analysis (Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Mellitus)
  732. Meta-analysis of HbA1c-lowering efficacy of dipeptidyl peptidase-4 inhibitors in combination with insulin in T2DM patients
  733. FC 125: Comparative Effectiveness of Dipeptidyl Peptidase-4 Inhibitors versus Sulfonylureas in Addition to Metformin: A Population-Based Cohort Study of Patientsย โ€ฆ
  734. Comment on: Monami et al. Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures: A Meta-analysis of Randomized Clinical Trials. Diabetes Care 2011; 34: 2474โ€“2476
  735. PDB22 potential budget impact of linagliptin in France estimated from current pattern of dipeptidyl peptidase 4 inhibitors prescriptions
  736. Repurposing of Dipeptidyl Peptidase-4 Inhibitors
  737. SARS-CoV-2 and diabetes: A potential therapeutic effect of dipeptidyl peptidase 4 inhibitors in diabetic patients diagnosed with COVID-19
  738. Identification of Dipeptidyl peptidase-4 (DPP-4) inhibitors as Potential Antidiabetic agents using Molecular docking study
  739. Comparisons of Efficacy Between Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase 4 Inhibitors Add-on to Metformin Therapy in Type 2ย โ€ฆ
  740. QSAR rationales for the dipeptidyl peptidase-4 (DPP-4) inhibitors: The imidazolopyrimidine amides
  741. Discovery of 3H-imidazo [4, 5-c] quinolin-4 (5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors: use of a carboxylate prodrug to improveย โ€ฆ
  742. DIPEPTIDYL PEPTIDASE-4 INHIBITORS-NEW POTENTIALS FOR TREATMENT OF TYPE 2 DIABETES MELLITUS: EXPERIENCE OF USE OF GALVUS MET INย โ€ฆ
  743. The efficacy and safety of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 agonists in pediatric patients with type 2 diabetes: a systematic review
  744. Adherence to Oral Antihyperglycemic Agents (Dipeptidyl Peptidase-4 Inhibitors and Biguanides) and Its Associated Factors in Patients with Type 2 Diabetes
  745. Factors associated with the discontinuation of dipeptidyl peptidase-4 inhibitors (DPP-4is) after initiation of insulin
  746. Incretin-based Therapies: Dipeptidyl Peptidase-4 Inhibitors
  747. โ€ฆย as dipeptidyl peptidase IV inhibitors: profile of clinical candidate (2R, 3S, 5R)-2-(2, 5-difluorophenyl)-5-[2-(methylsulfonyl)-2, 6-dihydropyrrolo [3, 4-c] pyrazol-5 (4H)-yl]ย โ€ฆ
  748. 4-arylcyclohexylalanine analogs as potent, selective, and orally active inhibitors of dipeptidyl peptidase IV
  749. Dipeptidyl Peptidase-4 Inhibitors Reduced Long-term Cardiovascular Risk in Japanese Diabetic Patients After Percutaneous Coronary Intervention via Insulin-likeย โ€ฆ
  750. Pooled patient level data are better suited than study level data to investigate the link between dipeptidyl peptidase-4 inhibitors and the risk of heart failure in type 2ย โ€ฆ
  751. A comparative study of the in vitro antioxidant activity of dipeptidyl peptidase-4 inhibitors
  752. Evaluation of Dipeptidyl Peptidase-4 Inhibitors versus Thiazolidinediones or Insulin in Patients with Type 2 Diabetes Uncontrolled with Metformin and aย โ€ฆ
  753. The Beneficial Effects of Switching from Dipeptidyl Peptidase-4 Inhibitors to Dulaglutide on Plasma Glucose and Hemoglobin A1c Levels: A Case Report of Fourย โ€ฆ
  754. Impact of standard-dose dipeptidyl peptidase-4 inhibitors on the incidence of graft-versus-host disease among diabetes mellitus patients undergoing allogeneicย โ€ฆ
  755. Optimization of 1, 4-diazepan-2-one containing dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes
  756. Role of Incretin, Incretin Analogues and Dipeptidyl Peptidase 4 Inhibitors in the Pathogenesis and Treatment of Diabetes Mellitus
  757. Role of incretin, incretin analogues and dipeptidyl peptidase 4 inhibitors in the pathogenesis and treatment of diabetes mellitus
  758. Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: the importance of the pharmacotherapeutic history
  759. 865-P: Hypoglycemia Risk Is Similar with Dipeptidyl Peptidase-4 Inhibitors (DPP-4i) Monotherapy vs. Metformin Monotherapy
  760. Research Progress in Dipeptidyl Peptidase-4 Inhibitors
  761. Effectiveness in clinical practice versus efficacy of dipeptidyl peptidase-4 inhibitors in clinical trials for type 2 diabetes: protocol for systematic review
  762. 122 Comparing dipeptidyl peptidase-4 inhibitors and sodium-glucose cotransporter-2 inhibitors on new-onset heart failure and myocardial infarction
  763. โ€ฆย utilization comparison of patients with type 2 diabetes on sodiumโ€“glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: evidence from 2015 toย โ€ฆ
  764. โ€ฆย Comparison to Evaluate the Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors (DPP4I) and Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2I) Added toย โ€ฆ
  765. Design and elaboration of a tractable tricyclic scaffold to synthesize druglike inhibitors of dipeptidyl peptidase-4 (DPP-4), antagonists of the Cโ€“C Chemokine Receptorย โ€ฆ
  766. Nonglycemic effects of dipeptidyl peptidase-4 inhibitors
  767. โ€ฆย Diabetes: Better Renal Outcomes in Patients with Type 2 Diabetes Taking Sodium-Glucose Cotransporter 2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors
  768. Cardiovascular outcomes during treatment with dipeptidyl peptidase-4 inhibitors depending on renal function and combination with metformin: a systematic review
  769. Association Between Dipeptidyl Peptidase-4 Inhibitors and Diabetic Retinopathy in Korean Patients With Type 2 Diabetes Mellitus: Nationwide Population-Basedย โ€ฆ
  770. Identification of Dipeptidyl Peptidase-4 and ฮฑ-Amylase Inhibitors from Melicope glabra (Blume) TG Hartley (Rutaceae) Using Liquid Chromatography Tandem Massย โ€ฆ
  771. โ€ฆย transโ€decalin spiroโ€ฮณโ€lactone, from pharaoh cuttlefish Sepia pharaonis: Twin inhibitors of inflammatory 5โ€lipoxygenase and serine protease dipeptidyl peptidaseโ€4
  772. Evaluation of Hypoglycaemic Effects of Dipeptidyl Peptidaseโ€“4 Inhibitors and Biguanide on Type-2 Diabetic subjects: A six months trial
  773. Impact of Dipeptidyl Peptidase-4 Inhibitors on The Risk of Cardiovacular-Related Hsopitalizations
  774. Therapeutic Role of Dipeptidyl Peptidase-4 Inhibitors in COVID-19
  775. โ€ฆย Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review
  776. # 6153 SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS VERSUS DIPEPTIDYL PEPTIDASE 4 INHIBITORS AS STABILIZERS OF HIF PATHWAY IN DIABETICย โ€ฆ
  777. Effect of dipeptidyl peptidase-4 inhibitors and sodium-glucose cotransporter-2 inhibitors on retinal complications in type 2 diabetic patients
  778. Dipeptidyl Peptidase 4 Inhibitors for Type 2 Diabetes and Relationships to Diabetic Macular Edema
  779. Comparison of Effect of Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors with Dipeptidyl Peptidase-4 (DPP-4) Inhibitors on HBA1c Level in Type 2 Diabetes inย โ€ฆ
  780. Dipeptidyl peptidase 4 inhibitors and bullous pemphigoidโˆ’ more evidence of a link: a report of three cases
  781. In silico discovery of potential inhibitors against Dipeptidyl Peptidase-4: A major biological target of type-2 diabetes mellitus
  782. Combined effect of sodiumโ€“glucose cotransporter 2 and dipeptidyl peptidaseโ€4 inhibitors for diabetic kidney disease
  783. The effect of dipeptidyl peptidase-4 inhibitors or curcumin on diet induced metabolic syndrome with cardiac dysfunction in rats
  784. 1138-P: Dipeptidyl Peptidase-4 Inhibitors Attenuate Thyroid-Stimulating Hormone Levels
  785. Assessing the association between dipeptidyl peptidase-4 inhibitors use and celiac disease through drug adverse event reporting
  786. Role of cardiovascular protection played by dipeptidyl peptidase 4 inhibitors
  787. EFFICACY OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS THERAPY IN DIFFERENT POPULATIONS
  788. Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome
  789. โ€ฆย of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes showing inadequate response to thrice-a-day treatment with ฮฑ-glucosidase inhibitors
  790. Association of sulphonylureas and dipeptidyl peptidase-4 inhibitors with cardiovascular disease: population-based cohort study
  791. Dipeptidyl peptidase 4 inhibitors reduce costs in T2DM management
  792. 4-Aminophenylalanine and 4-aminocyclohexylalanine derivatives as potent, selective, and orally bioavailable inhibitors of dipeptidyl peptidase IV
  793. The mechanism of the action of dipeptidyl peptidase-4 inhibitors and its use in type 2 diabetes
  794. Association of sodiumโ€glucose cotransporterโ€2 inhibitors versus dipeptidyl peptidaseโ€4 inhibitors with time to dementia: a populationโ€based cohort study
  795. Effects of Increasing Metformin Dose vs Adding/Switching to Dipeptidyl Peptidase-4 Inhibitors on Glycemic Control in Patients with Type 2 Diabetes
  796. Are dipeptidyl peptidase-4 inhibitors effective and safe in long term when added to ongoing therapies of diabetics? a real-life study in tertiary referral center
  797. In silico study of four alkaloids as dipeptidyl peptidase-4 (DPP4) inhibitors to generate anti-diabetics effect
  798. โ€ฆย -P: A Population-Based Assessment of the Risk of Severe Hypoglycemia with Concomitant Use of Sulfonylureas and Peptidomimetic Dipeptidyl Peptidase-4 Inhibitors
  799. Investigation of cardiotoxicity by dipeptidyl-peptidase-4 inhibitors in a human cardiomyocyte cell line as well as in samples from chronic heart failure patients
  800. Study the effect of Dipeptidyl Peptidase 4 Inhibitors as an Antidiabetic in Type 2 Diabetes Mellitus (T2DM)
  801. Evaluation of Efficacy and Safety for Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients
  802. The Effect of Dipeptidyl Peptidase-4 Inhibitors on Carotid Intima-media Thickness in Patients With Type 2 Diabetes Mellitus: a Meta-analysis
  803. Diabetes and cardiovascular risk: are dipeptidyl peptidase-4 inhibitors beneficial?
  804. โ€ฆย of 3-aminomethyl-1, 2-dihydro-4-phenyl-1-isoquinolones: a new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form aย โ€ฆ
  805. Patient-Reported Outcomes of Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review
  806. Electronic medical records-based comparison of glycemic control efficacy between sulfonylureas and dipeptidyl peptidase-4 inhibitors added on to metforminย โ€ฆ
  807. Sulfonylureas or dipeptidyl peptidase (DPP-4) inhibitors in the management of type 2 diabetes: debate is not yet closed
  808. Response to Letter Regarding Article,โ€œCardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylurea as Add-on Therapy for Type 2ย โ€ฆ
  809. Effect of dipeptidyl peptidase-4 inhibitors on cardiovascular outcome
  810. Meta-analysis of cardiovascular outcome trials assessing the cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetesย โ€ฆ
  811. Dipeptidyl Peptidase-4 Inhibitors Do Not Exacerbate Heart Failure
  812. Synthesis and SAR Study of Chloro-Retrochalcone Derivatives as Dipeptidyl Peptidase 4 Inhibitors with Anti-Inflammatory Effects
  813. BENEFICIAL EFFECTS OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS ON VASCULAR DYSFUNCTION
  814. Impact of antidiabetic treatment with dipeptidyl peptidase-4 inhibitors on the risk of cardiac arrhythmias among patients with type 2 diabetes mellitus
  815. The Safety Profile Comparison Between Dipeptidyl Peptidase-4 Inhibitors and Sulfonylureas in Diabetic Patients: A Systematic Review and Meta-Analysis
  816. Dipeptidyl Peptidase-4 Inhibitors Significantly Reduce the Incidence of First Cardiovascular Events in Diabetic Patients
  817. Dipeptidyl-peptidase-4 Inhibitors for Treatment of Type 2 Diabetes
  818. PDB10 A Meta-Analysis of Efficacy and Safety of Dipeptidyl Peptidase-4 [Dpp-4] Inhibitors in Type 2 Diabetes
  819. Emerging GLP-1 analogues and dipeptidyl peptidase 4 (DPP-4) inhibitors
  820. Cardiovascular Outcome Trials with Dipeptidyl Peptidase-4 Inhibitors
  821. A DIFFERENTIATED APPROACH TO PRESCRIBING DIPEPTIDYL PEPTIDASE-4 INHIBITORS
  822. A Prospective Observational Study of Comparison, Safety, and Efficacy of Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus in A Tertiaryย โ€ฆ
  823. Genetic predictors of the pharmacological effects of dipeptidyl peptidase-4 inhibitors and sulfonylureas in patients with type 2 diabetes mellitus
  824. Effect of dipeptidyl peptidase-4 inhibitors linagliptin on the expression of serum pigment epithelium-derived factor in type 2 diabetes patients
  825. Prescribing pattern of dipeptidyl peptidase 4 inhibitors and level of HBA1C target achievements among outpatients with type 2 diabetes mellitus in a Malaysianย โ€ฆ
  826. 2209-PUB: Factors Associated with Switching from Sulfonylureas (SUs) to Dipeptidyl Peptidase-4 Inhibitors (DPP-4i) among Individuals with Type 2 Diabetes in theย โ€ฆ
  827. Diabetes Mellitus: Dipeptidyl Peptidase 4 Inhibitors and Cardiovascular Outcomes
  828. Real-world adherence, persistence, and in-class switching during use of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis involving 594,138ย โ€ฆ
  829. Dipeptidyl Peptidase 4 Inhibitors and the Risk of Heart Failure 126
  830. Risk of Pancreatic Cancer and Use of Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes: A Propensity Score-Matching Analysis
  831. Lower COVID-19 Mortality in Patients with Type 2 Diabetes Mellitus Taking Dipeptidyl Peptidase-4 Inhibitors: Results from a Turkish Nationwide Study
  832. Effect of Dipeptidyl Peptidase-4 Inhibitors on Plasma Adiponectin: A Systematic Review and Meta-Analysis of
  833. Cardiovascular Preventing Effects of Dipeptidyl Peptidase-4 Inhibitors: Beyond Glucagon-Like Peptide-1
  834. Dipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes mellitus
  835. Correction: The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
  836. MO38-5 Dipeptidyl peptidase-4 inhibitors and risk of gall bladder cancer in type 2 diabetes patients: A meta-analytic synthesis
  837. Changes in prescribing of sodium-glucose co-transporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors in Singapore
  838. Emerging Role of Dipeptidyl Peptidase-4 Inhibitors in the Management of Type 2 Diabetes Mellitus
  839. Efficacy of switching from dipeptidyl peptidase-4 inhibitors to dulaglutide in patients with type 2 diabetes
  840. Comparison of cardiovascular and renal outcomes between sodium glucose coโ€“transporterโ€“2 and dipeptidyl peptidaseโ€“4 inhibitors among type 2 diabetes patients: aย โ€ฆ
  841. Dipeptidyl peptidase-4 inhibitors Mitigates Glycemic Variability in Metformin based Multiple Daily injected Type 2 Diabetes, a Prospective Randomized Controlled Trial
  842. PDB101 PATTERNS OF ADHERENCE, PERSISTENCE, AND SWITCHING AMONG AUSTRALIANS PRESCRIBED DIPEPTIDYL PEPTIDASE-4 INHIBITORS
  843. O145 Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: Meta-analysis of randomized clinical trials
  844. Dipeptidyl Peptidase-4 Inhibitors, a New Option for the Management of Type 2 Diabetes Mellitus
  845. Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients: A Meta-Analysis of 95 Trials
  846. Risk of Dipeptidyl-Peptidase-4 (Dpp-4) Inhibitors On Site-Specific Cancer: A Systematic Review And Meta-Analysis
  847. Comparing the Risk of Heart Failure Among Different Dipeptidyl Peptidase 4 Inhibitors
  848. Effect of Add-On Therapy of Sodium-Glucose Cotransporter 2 Inhibitors and Dipeptidyl Peptidase 4 Inhibitors on Adipokines in Type 2 Diabetes Mellitus
  849. Dipeptidyl peptidase-4 inhibitors induced inflammatory bowel disease in type 2 diabetes patients: A case control study in a South-Indian tertiary care hospital
  850. Research progress of dipeptidyl peptidase 4 inhibitors on healing of chronic diabetic foot ulcers
  851. Development of analytical methods for quantitative estimation of Dipeptidyl Peptidase-4 inhibitors in bulk and Pharmaceutical formulations
  852. DIPEPTIDYL PEPTIDASE-4 INHIBITORS AND CARDIOVASCULAR OUTCOMES: META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS WITH 55,141ย โ€ฆ
  853. EFFICACY OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS FOR CARDIAC FUNCTION IN DIABETIC PATIENTS WITH ISCHEMIC HEART DISEASE
  854. Evolution of the Market for oral Antidiabetic agents In Canada after Introduction of Dipeptidyl Peptidase-4 Inhibitors
  855. POTENTIALS FOR USE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS IN TYPE 2 DIABETES MELLITUS: INITIATION AND CONTINUATION OF THERAPY
  856. Dipeptidyl peptidase-4 inhibitors and bone fractures: A Meta-analysis of randomized clinical trials
  857. Trust and VERIFY: the role of combined treatment with metformin and dipeptidyl peptidase-4 inhibitors in new-onset diabetes type 2
  858. โ€ฆย ASSESSMENT OF SWITCHING FROM DIPEPTIDYL PEPTIDASE-4 INHIBITORS TO SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITORS OR GLUCAGON-LIKEย โ€ฆ
  859. Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes patients: a propensity scoreย โ€ฆ
  860. Real world evidence on the disparities in prescribing of dipeptidyl peptidase-4 inhibitors in UK primary care
  861. COMPARATIVE SAFETY OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS AND SULFONYLUREAS IN OLDER ADULTS ACROSS LEVELS OF FRAILTY
  862. Factors associated with physician prescribing behavior of dipeptidyl peptidase-4 inhibitors for type 2 diabetes in the US outpatient population
  863. Costs for Diabetic Patients Receiving Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in US Medicare and Commercial Insurance Plans
  864. High concentrations of dipeptidyl peptidase-4 inhibitors suppressed lipopolysaccharide-induced inflammatory cytokine expression in U937 cells
  865. Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors
  866. PDB15-CARDIOVASCULAR SAFETY OF EMPAGLIFLOZIN VERSUS DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS: SYSTEMATIC LITERATURE REVIEW ANDย โ€ฆ
  867. Comparative effects of sodium glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP4) inhibitors on new-onset atrial fibrillation and strokeย โ€ฆ
  868. Cardiovascular safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus
  869. Treatment with dipeptidyl peptidase-4 inhibitors may induce bullous pemphigoid in patients with type 2 diabetes
  870. DIPEPTIDYL PEPTIDASE-4 INHIBITORS WERE ASSOCIATED WITH THE REDUCED LONG-TERM RISK OF ADVERSE CARDIOVASCULAR EVENTS IN JAPANESEย โ€ฆ
  871. Identification of dipeptidyl peptidase-4 inhibitors among boioactive peptides derived from whey proteins
  872. Beneficial Impact of Dipeptidyl-peptidase-4 inhibitors on Mortality of Patients With Hospitalized Heart Failure Patients With Diabetes Mellitus
  873. The Effect Of Dipeptidyl-Peptidase-4 Inhibitors On Asthma Control: An Administrative Database Study To Evaluate A Potential Pathophysiological Relationship
  874. DIPEPTIDYL PEPTIDASE-4 INHIBITORS IN COMBINATION WITH METFORMIN: EXPERIENCE OF USE OF GALVUS MET IN REAL-LIFE CLINICAL PRACTICE INย โ€ฆ
  875. Dipeptidyl Peptidase-4 Inhibitors and Joint Pain: A Retrospective Cohort Study of Older Veterans with Type 2 Diabetes Mellitus
  876. Systematic Review of Economic Evaluations of Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus
  877. 3D QSAR and Pharmacophore Identification of Heteroarylpiperazine-Substituted l-Prolylthiazolidines as Dipeptidyl Peptidase-4 Inhibitors
  878. P0633 EFFECT OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS ON CISPLATIN-INDUCED ACUTE NEPHROTOXICITY IN CANCER PATIENTS WITH DIABETESย โ€ฆ
  879. 1258-P: Physician Survey on Discontinuing Dipeptidyl Peptidase-4 Inhibitors (DPP-4is) following Insulin Initiation in Patients with Type 2 Diabetes (T2D) in the US
  880. Emerging Safety Issues of Dipeptidyl Peptidase-4 Inhibitors and Sodium Glucose Cotransporter 2 Inhibitors: How to Interpret and Apply in Clinical Practice
  881. Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy.
  882. Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2015; 39: 342-7)
  883. Cardiovascular Outcome Trials of Incretin Therapy (Dipeptidyl Peptidase-4 Inhibitors/Glucagon-Like Peptide-1 Receptor Agonist)
  884. Synthesis and structureโ€“activity relationships of potent 4-fluoro-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors
  885. EFFICACY AND TOLERABILITY OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS IN PATIENTS WITH DIABETES MELLITUS AND RENAL IMPAIRMENT: A SYSTEMATICย โ€ฆ
  886. Response: Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients (Diabetesย โ€ฆ
  887. Economic Impact of Combining Metformin with Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients with Renal Impairment in Spanish Patients (Diabetes Metab Jย โ€ฆ
  888. Two-Year Assessment of the Therapeutic Efficacy of Dipeptidyl Peptidase-4 Inhibitors or Sulfonylureas in Japanese Drug-Naive Patients With Type 2 Diabetes (JDDMย โ€ฆ
  889. Differences in Cardiovascular and Renal Outcomes Between Sodium Glucose Co-Transporter-2 and Dipeptidyl Peptidase-4 Inhibitors Among Type 2 Diabetesย โ€ฆ
  890. Do sodium glucose transporter-2 inhibitors reduce HbgA1c levels more than dipeptidyl peptidase-4 inhibitors?
  891. Metformin in Combination With Dipeptidyl Peptidase-4 Inhibitors or Sulfonylureas in The Treatment of Type 2 Diabetes: Clinical And Economic Impact
  892. Impact of Systemic Dipeptidyl Peptidase-4 (DPP-4) Inhibitors on Treatment Outcomes for Diabetic Macular Edema (DME) in the VISTA and VIVID trials
  893. Clinical Outcomes and Health Care Costs Evaluation of Sulfonamides and Thiazolidinediones Compared with Dipeptidyl Peptidase 4 Inhibitors for the Treatment ofย โ€ฆ
  894. Dipeptidyl Peptidase-4 Inhibitors May Reduce the Risk of Major Adverse Cardiovascular Events and All-cause Mortality In Patients With Type 2 Diabetes: Metaย โ€ฆ
  895. 151-LB: High Risk of Krebs Von Den Lungen-6 (kL-6) Elevation when Dipeptidyl Peptidase-4 Inhibitors and Amiodarone Are Prescribed Simultaneously
  896. Synthesis and structure: activity relationships of potent 1-(2-substituted-aminoacetyl)-4-fluoro-2-cyanopyrrolidine dipeptidyl peptidase 4 inhibitors
  897. Outcomes Associated With the Adjunctive Use of Dipeptidyl Peptidase-4 Inhibitors With Insulin Versus Other Antihyperglycemic Medications in Patients Withย โ€ฆ
  898. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: a systematic review and meta-analysis of randomized and observational studies
  899. Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Basedย โ€ฆ
  900. Comparison of glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mettilus
  901. Response: Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Realย โ€ฆ
  902. 4-Amino cyclohexylglycine analogues as potent dipeptidyl peptidase IV inhibitors
  903. Differential Effects of Thiazolidinediones and Dipeptidyl Peptidase-4 Inhibitors on Insulin Resistance and b-Cell Function in Type 2 Diabetes Mellitus: Aย โ€ฆ
  904. โ€ฆย trials of sodium glucose co-transporter 2 inhibitors, glucagon-like peptide-1 receptor analogues and dipeptidyl peptidase-4 inhibitors to a representative routineย โ€ฆ
  905. โ€ฆย HbA1C Reduction Associated With Initial Versus Sequential Combination Therapy With Pioglitazone (PIO) and Dipeptidyl Peptidase-4 Inhibitors (DPP4i) in Patientsย โ€ฆ
  906. Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohortย โ€ฆ
  907. TREATMENT OPTIMIZATION WITH SODIUM/GLUCOSE COTRANSPORTER-2 INHIBITORS, DIPEPTIDYL PEPTIDASE-4 INHIBITORS OR GLYCAGONE LIKEย โ€ฆ
  908. Combined use of dipeptidyl peptidase-4 inhibitors and metformin reduces blood sugar level and improves pancreatic islet ฮฒ cell function in the treatment of typeย โ€ฆ
  909. Cardiovascular Effectiveness of Empagliflozin Compared to Glucagon Like Peptide-1 Receptor Agonists and to Dipeptidyl Peptidase-4 Inhibitors in Older Patientsย โ€ฆ
  910. Cost-Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On toย โ€ฆ
  911. Glucagon-Like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors, and Risk of Acute Pancreatitis: A Meta-analysis of Randomized Clinical Trial andย โ€ฆ
  912. Reply to:โ€œComment on โ€˜Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide caseย โ€ฆ
  913. โ€ฆย COTRANSPORTER-2 (SGLT2) INHIBITORS, GLUCAGON-LIKE PEPTIDE 1 (GLP-1) RECEPTOR AGONISTS, DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS: Aย โ€ฆ
  914. A Real-World Disproportionality Analysis of Atrial Fibrillation Adverse Events for Glucagon Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
  915. New trends in the treatment of type 2 Diabetes Mellitus: a review of Thiazolidinediones, GLP-1 agonists, Dipeptidyl Peptidase-4 inhibitors, and SGLT-2 inhibitors
  916. Novel series of 3-amino-N-(4-aryl-1, 1-dioxothian-4-yl) butanamides as potent and selective dipeptidyl peptidase IV inhibitors
  917. Soluble Dipeptidyl Peptidase-4 Induces Endothelial Dysfunction by the Release of Vasoconstrictor Prostanoids: Protective Effect of Dipeptidyl Peptidase Inhibitors
  918. Angioprotektivnoe properties lowering drugs from the group of inhibitors of dipeptidyl peptidase-4
  919. FC 2-6: Increased risk of bullous pemphigoid in patients with diabetes mellitus receiving dipeptidyl peptidase-4 inhibitors: A nationwide populationbased study
  920. Reply to the letter by P. Guillausseau Regarding โ€œSulfonylureas or Dipeptidyl Peptidase (DPP-4) Inhibitors in the Management of Type 2 Diabetes: Debate Is Not Yetย โ€ฆ
  921. Dipeptidyl peptidase 4 inhibitors and Glucagon-like peptide-1 receptor agonist mitigate inflammation and fibrosis in models of Non-alcoholic steatohepatitis and biliaryย โ€ฆ
  922. Are Dipeptidyl Peptidase (DPP)-4 Inhibitors Safe in Patients with Heart Failure?
  923. Influence of inhibitors of dipeptidyl peptidase-4 (DPP-4) on naloxone-induced morphine withdrawal signs in rats
  924. โ€ฆย Etanercept; Fondaparinux Hepatotoxicity in a 6-Year-Old Child; Bullous Pemphigoid Induced by Dipeptidyl Peptidase-4 Inhibitors; Severe Neuroleptic Malignantย โ€ฆ
  925. UNEXPECTED ADVERSE REACTIONS OF THE DRUGS OF THE GROUP OF INHIBITORS OF DIPEPTIDYL PEPTIDASE-4
  926. โ€ฆย of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus on glucagon-like peptide-1 receptor agonists or dipeptidyl peptidase-4 inhibitors as add-onย โ€ฆ
  927. Sodium-glucose Cotransporter-2 Inhibitors as Modulator of Dipeptidyl Peptidase-4 in Diabetes
  928. Health Expenditure Comparison of Diabetic Patients on Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Vs Dipeptidyl Peptidase-4 (DPP4) Inhibitors
  929. โ€ฆย 24-hour glucose profile and glycemic variability evaluated by continuous glucose monitoring in patients with type 2 diabetes receiving dipeptidyl peptidase-4 inhibitorsย โ€ฆ
  930. Diabetes mellitus therapy adherence and therapy characterization in Northeast Portugal: classical vs dipeptidyl peptidase iv (dpp-4) inhibitors
  931. Screening for Dipeptidyl Peptidase IV (DPP-4) inhibitors from Thai herbal medicines use in traditional anti-diabetes recipe
  932. Substituted pyrrolidine-2, 4-dicarboxylic acid amides as potent dipeptidyl peptidase IV inhibitors
  933. Targeting Dipeptidyl peptidase-4 (DPP4) by peptide inhibitors for the management of Type-2 diabetes and its complications.
  934. dipeptidyl-peptidase IV (DPP-4) inhibitors at the highest maintenance doses evaluated in this meta-analysis and systematic review of the efficacy of incretin-basedย โ€ฆ
  935. OUTCOME EVALUATION OF DIPEPTIDYL PEPTIDASE 4 (DPP4) INHIBITORS AND ITS COMBINATION ON GLYCEMIC CONTROL OF TYPE 2
  936. Synthesis and structureโ€“activity relationships of potent 3-or 4-substituted-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors
  937. Synthesis and Structureโ€“Activity Relationships of Potent 1-(2-Substituted-aminoacetyl)-4-fluoro-2-cyanopyrrolidine Dipeptidyl Peptidase IV Inhibitors
  938. Outcome evaluation of dipeptidyl peptidase 4 (DPP4) inhibitors and its combination on glycemic control of type 2 diabetes mellitus patients at Putrajaya Hospital
  939. Effect of Dipeptidyl Peptidase Inhibitors-4 and Sulfonylurea on Serum Adiponectin Levels in Patients with Newly Diagnosed Type 2 Diabetes Mellitus.
  940. In Silico Design, Synthesis and In Vitro Evaluation of Quinazolinone Derivatives as Dipeptidyl Peptidase-4 (DPP-IV) Inhibitors
  941. Synthesis, Docking and In-Vitro Studies of Quinazoline Derivatives as Dipeptidyl Peptidase-4 and ฮ‘-Amylase Inhibitors for Treating Diabetes
  942. A Decision-Focused Network Meta-Analysis (NMA) of Dipeptidyl Peptidase-4 (DPP4) Inhibitors Used In Combination With Metformin And A Sulfonylurea For Theย โ€ฆ
  943. Comparison of efficacies of a dipeptidyl peptidase 4 inhibitor and ฮฑ-glucosidase inhibitors in oral carbohydrate and meal tolerance tests and the effects of theirย โ€ฆ
  944. โ€ฆย and biological evaluation of 4-fluoropyrrolidine-2-carbonitrile and octahydrocyclopenta [b] pyrrole-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitors
  945. 1, 3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo [a] quinolizine dipeptidyl peptidase IV inhibitors
  946. ฮณ-Amino-Substituted Analogues of 1-[(S)-2,4-Diaminobutanoyl]piperidine as Highly Potent and Selective Dipeptidyl Peptidase II Inhibitors
  947. Structural Requirements for some 3-amino-Nsubstituted-4-(substituted phenyl) Butanamides as Dipeptidyl Peptidase-IV Inhibitors Using 3D-QSAR and Molecularย โ€ฆ
  948. Substituted piperidinyl glycinyl 2-cyano-4, 5-methano pyrrolidines as potent and stable dipeptidyl peptidase IV inhibitors
  949. โ€œDipeptidyl Peptidase Inhibitorsโ€ Patent Act, Secs. 21 (2) No. 1, 34 (4)
  950. (3R, 4S)-4-(2, 4, 5-Trifluorophenyl)-pyrrolidin-3-ylamine inhibitors of dipeptidyl peptidase IV: Synthesis, in vitro, in vivo, and X-ray crystallographic characterization
  951. โ€ฆย tetrahydropyran analogs as dipeptidyl peptidase IV inhibitors: Profile of clinical candidate (2R, 3S, 5R)-2-(2, 5-difluorophenyl)-5-(4, 6-dihydropyrrolo [3, 4-c] pyrazol-5ย โ€ฆ
  952. Design and synthesis of 4โ€(2, 4, 5โ€trifluorophenyl) butaneโ€1, 3โ€diamines as dipeptidyl peptidase IV inhibitors
Related Posts

BMI-1

Inhibition Of Advanced Glycation End Products

Pancreatic Cancer (Medicinal Plant Prevention)

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

0
    0
    Your Cart
    Your cart is emptyReturn to Shop
    Continue Shopping